U.S. patent application number 12/694238 was filed with the patent office on 2012-03-15 for influenza nucleic acid molecules and vaccines made therefrom.
Invention is credited to Matthew P. Morrow, David B. Weiner, Jian Yan.
Application Number | 20120064116 12/694238 |
Document ID | / |
Family ID | 44309124 |
Filed Date | 2012-03-15 |
United States Patent
Application |
20120064116 |
Kind Code |
A9 |
Weiner; David B. ; et
al. |
March 15, 2012 |
INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM
Abstract
Provided herein are nucleic acid sequences that encode novel
consensus amino acid sequences of HA hemagglutinin, as well as
genetic constructs/vectors and vaccines expressing the sequences.
Also provided herein are methods for generating an immune response
against one or more Influenza A serotypes using the vaccines that
are provided.
Inventors: |
Weiner; David B.; (Merion,
PA) ; Yan; Jian; (Havertown, PA) ; Morrow;
Matthew P.; (Philadelphia, PA) |
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20110182938 A1 |
July 28, 2011 |
|
|
Family ID: |
44309124 |
Appl. No.: |
12/694238 |
Filed: |
January 26, 2010 |
Current U.S.
Class: |
424/209.1;
424/184.1; 435/320.1; 514/44R; 536/23.1 |
Current CPC
Class: |
A61K 2039/54 20130101;
A61K 39/145 20130101; A61K 45/06 20130101; A61K 2039/53 20130101;
A61P 37/00 20180101; A61K 39/12 20130101; C12N 2760/16134 20130101;
A61K 31/7088 20130101; A61P 31/16 20180101 |
Class at
Publication: |
424/209.1;
536/23.1; 435/320.1; 514/44.R; 424/184.1 |
International
Class: |
A61K 39/145 20060101
A61K039/145; A61K 39/00 20060101 A61K039/00; A61K 31/7088 20060101
A61K031/7088; C07H 21/04 20060101 C07H021/04; C12N 15/63 20060101
C12N015/63 |
Claims
1. An isolated nucleic acid molecule comprising one or more nucleic
acid sequences selected from the group consisting of 1) a selected
from the group consisting of: SEQ ID NO:1, a nucleic acid sequence
that is 95% homologous to SEQ ID NO:1; a fragment of SEQ ID NO:1
comprising at least 60 nucleotides, and a nucleic acid sequence
that is 95% homologous to a fragment of SEQ ID NO:1 comprising at
least 60 nucleotides; 2) a nucleic acid sequence is selected from
the group consisting of: SEQ ID NO:3, a nucleic acid sequence that
is 95% homologous to SEQ ID NO:3; a fragment of SEQ ID NO:3
comprising at least 60 nucleotides, and a nucleic acid sequence
that is 95% homologous to a fragment of SEQ ID NO:3 comprising at
least 60 nucleotides; 3) a nucleic acid sequence is selected from
the group consisting of: SEQ ID NO:6, a nucleic acid sequence that
is 95% homologous to SEQ ID NO:6; a fragment of SEQ ID NO:6
comprising at least 60 nucleotides, and a nucleic acid sequence
that is 95% homologous to a fragment of SEQ ID NO:6 comprising at
least 60 nucleotides; 4) a nucleic acid sequence is selected from
the group consisting of: SEQ ID NO:9, a nucleic acid sequence that
is 95% homologous to SEQ ID NO:9; a fragment of SEQ ID NO:9
comprising at least 60 nucleotides, and a nucleic acid sequence
that is 95% homologous to a fragment of SEQ ID NO:9 comprising at
least 60 nucleotides; 5) a nucleic acid sequence is selected from
the group consisting of: SEQ ID NO:11, a nucleic acid sequence that
is 95% homologous to SEQ ID NO:11; a fragment of SEQ ID NO:11
comprising at least 60 nucleotides, and a nucleic acid sequence
that is 95% homologous to a fragment of SEQ ID NO:11 comprising at
least 60 nucleotides; 6) a nucleic acid sequence is selected from
the group consisting of: SEQ ID NO:13, a nucleic acid sequence that
is 95% homologous to SEQ ID NO:13; a fragment of SEQ ID NO:13
comprising at least 60 nucleotides, and a nucleic acid sequence
that is 95% homologous to a fragment of SEQ ID NO:13 comprising at
least 60 nucleotides; and 7) a nucleic acid sequence is selected
from the group consisting of: SEQ ID NO:15, a nucleic acid sequence
that is 95% homologous to SEQ ID NO:15; a fragment of SEQ ID NO:15
comprising at least 60 nucleotides, and a nucleic acid sequence
that is 95% homologous to a fragment of SEQ ID NO:15 comprising at
least 60 nucleotides.
2. The isolated nucleic acid molecule of claim 1 comprising a
nucleic acid sequence selected from the group consisting of: SEQ ID
NO:1, SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:11, SEQ ID
NO:13 and SEQ ID NO:15.
3. The isolated nucleic acid molecule of claim 1 comprising a
nucleic acid sequence selected from the group consisting of: a
nucleic acid sequence that is 95% homologous to SEQ ID NO:1, a
nucleic acid sequence that is 95% homologous to SEQ ID NO:3, a
nucleic acid sequence that is 95% homologous to SEQ ID NO:6, a
nucleic acid sequence that is 95% homologous to SEQ ID NO:9, a
nucleic acid sequence that is 95% homologous to SEQ ID NO:11, a
nucleic acid sequence that is 95% homologous to SEQ ID NO:13, and a
nucleic acid sequence that is 95% homologous to SEQ ID NO:15.
4. The isolated nucleic acid molecule of claim 1 comprising a
nucleic acid sequence selected from the group consisting of: a
nucleic acid sequence that is 98% homologous to SEQ ID NO:1, a
nucleic acid sequence that is 98% homologous to SEQ ID NO:3, a
nucleic acid sequence that is 98% homologous to SEQ ID NO:6, a
nucleic acid sequence that is 98% homologous to SEQ ID NO:9, a
nucleic acid sequence that is 98% homologous to SEQ ID NO:11, a
nucleic acid sequence that is 98% homologous to SEQ ID NO:13, and a
nucleic acid sequence that is 98% homologous to SEQ ID NO:15.
5. The isolated nucleic acid molecule of claim 1 comprising a
nucleic acid sequence selected from the group consisting of: SEQ ID
NO:1, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:13, and SEQ ID NO:15, and
a nucleic acid sequence that encodes an IgE leader sequence.
6. An expression vector comprising a nucleic acid sequence of claim
1 operably linked to regulatory elements.
7. An expression vector comprising a nucleic acid sequence of claim
1 operably linked to regulatory elements that are functional in a
human cell.
8. The expression vector of claim 7 wherein said expression vector
is a plasmid.
9. The expression vector of claim 8 wherein said expression vector
is pGX2009.
10. A composition comprising a) a plurality of one or more nucleic
acid molecules comprising one or more nucleic acid sequences
selected from the group consisting of: 1) a selected from the group
consisting of: SEQ ID NO:1, a nucleic acid sequence that is 95%
homologous to SEQ ID NO:1; a fragment of SEQ ID NO:1 comprising at
least 60 nucleotides, and a nucleic acid sequence that is 95%
homologous to a fragment of SEQ ID NO:1 comprising at least 60
nucleotides; 2) a nucleic acid sequence is selected from the group
consisting of SEQ ID NO:3, a nucleic acid sequence that is 95%
homologous to SEQ ID NO:3; a fragment of SEQ ID NO:3 comprising at
least 60 nucleotides, and a nucleic acid sequence that is 95%
homologous to a fragment of SEQ ID NO:3 comprising at least 60
nucleotides; 3) a nucleic acid sequence is selected from the group
consisting of: SEQ ID NO:6, a nucleic acid sequence that is 95%
homologous to SEQ ID NO:6; a fragment of SEQ ID NO:6 comprising at
least 60 nucleotides, and a nucleic acid sequence that is 95%
homologous to a fragment of SEQ ID NO:6 comprising at least 60
nucleotides; 4) a nucleic acid sequence is selected from the group
consisting of: SEQ ID NO:9, a nucleic acid sequence that is 95%
homologous to SEQ ID NO:9; a fragment of SEQ ID NO:9 comprising at
least 60 nucleotides, and a nucleic acid sequence that is 95%
homologous to a fragment of SEQ ID NO:9 comprising at least 60
nucleotides; 5) a nucleic acid sequence is selected from the group
consisting of: SEQ ID NO:11, a nucleic acid sequence that is 95%
homologous to SEQ ID NO:11; a fragment of SEQ ID NO:11 comprising
at least 60 nucleotides, and a nucleic acid sequence that is 95%
homologous to a fragment of SEQ ID NO:11 comprising at least 60
nucleotides; 6) a nucleic acid sequence is selected from the group
consisting of: SEQ ID NO:13, a nucleic acid sequence that is 95%
homologous to SEQ ID NO:13; a fragment of SEQ ID NO:13 comprising
at least 60 nucleotides, and a nucleic acid sequence that is 95%
homologous to a fragment of SEQ ID NO:13 comprising at least 60
nucleotides; and 7) a nucleic acid sequence is selected from the
group consisting of: SEQ ID NO:15, a nucleic acid sequence that is
95% homologous to SEQ ID NO:15; a fragment of SEQ ID NO:15
comprising at least 60 nucleotides, and a nucleic acid sequence
that is 95% homologous to a fragment of SEQ ID NO:15 comprising at
least 60 nucleotides; and b) one or more additional nucleic acid
sequences that encode one or more proteins selected from the group
consisting of one or more of: an influenza A hemaggultinin H1, an
influenza A hemaggultinin H2, an influenza A hemaggultinin H3,
influenza A H4 influenza A hemaggultinin H5, an influenza A
hemaggultinin H3, influenza A hemaggultinin H5, influenza A N1 . .
. influenza A hemaggultinin H6, an influenza A hemaggultinin H7,
influenza A hemaggultinin H5, influenza A hemaggultinin H6, an
influenza A hemaggultinin H7, an influenza A hemaggultinin H8, an
influenza A hemaggultinin H9, an influenza A hemaggultinin H10, an
influenza A hemaggultinin H11, an influenza A hemaggultinin H12,
influenza A H13 influenza A hemaggultinin H14, an influenza A
hemaggultinin H15, influenza A hemaggultinin H16, an influenza A
neuraminidase N1, an influenza A neuraminidase N2, an influenza A
neuraminidase N3, an influenza A neuraminidase N4, an influenza A
neuraminidase N5, an influenza A neuraminidase N6, an influenza. A
neuraminidase N7, an influenza A neuraminidase N8, an influenza A
neuraminidase N9, an influenza B hemaggultinin and an influenza B
neuraminidase.
11. The composition of claim 10 wherein said one or more additional
nucleic acid sequences are on a plurality of one or more different
nucleic acid molecules from the plurality of nucleic acid molecules
set forth in section a).
12. The composition of claim 10 wherein the plurality of nucleic
acid molecules set forth in section a) comprises one or more
nucleic acid sequences selected from the group consisting of: SEQ
ID NO:1, SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:11, SEQ
ID NO:13 and SEQ ID NO:15.
13. The composition of claim 10 wherein the plurality of nucleic
acid molecules set forth in section a) comprises one or more
nucleic acid sequences selected from the group consisting of: a
nucleic acid sequence that is 95% homologous to SEQ ID NO:1, a
nucleic acid sequence that is 95% homologous to SEQ ID NO:3, a
nucleic acid sequence that is 95% homologous to SEQ ID NO:6, a
nucleic acid sequence that is 95% homologous to SEQ ID NO:9, a
nucleic acid sequence that is 95% homologous to SEQ ID NO:11, a
nucleic acid sequence that is 95% homologous to SEQ ID NO:13, and a
nucleic acid sequence that is 95% homologous to SEQ ID NO:15.
14. The composition of claim 10 wherein the plurality of nucleic
acid molecules set forth in section a) comprises one or more
nucleic acid sequences selected from the group consisting of: a
nucleic acid sequence that is 98% homologous to SEQ ID NO:1, a
nucleic acid sequence that is 98% homologous to SEQ ID NO:3, a
nucleic acid sequence that is 98% homologous to SEQ ID NO:6, a
nucleic acid sequence that is 98% homologous to SEQ ID NO:9, a
nucleic acid sequence that is 98% homologous to SEQ ID NO:11, a
nucleic acid sequence that is 98% homologous to SEQ ID NO:13, and a
nucleic acid sequence that is 98% homologous to SEQ ID NO:15.
15. The composition of claim 10 wherein the nucleic acid sequences
set forth in a) and b) are each operably linked to regulatory
elements.
16. The composition of claim 10 wherein the nucleic acid sequences
set forth in a) and b) are each operably linked to regulatory
elements that are functional in a human cell.
17. The composition of claim 10 wherein the nucleic acid sequences
set forth in a) and b) are part of one or more expression
vectors
18. The composition of claim 10 wherein the one or more expression
vectors are plasmids.
19. The composition of claim 10 comprising pGX2009 and/or
pGX2006.
20. The composition of claim 10 comprising one or more of: a
nucleic acid sequence comprising SEQ ID NO:1; a nucleic acid
sequence comprising SEQ ID NO:6; a nucleic acid sequence comprising
SEQ ID NO:9; a nucleic acid sequence comprising SEQ ID NO:13; a
nucleic acid sequence that encodes an influenza A hemaggultinin H1;
and a nucleic acid sequence that encodes an influenza A
hemaggultinin H3.
21. The composition of claim 10 wherein the nucleic acid sequence
that encodes an influenza A hemaggultinin H1 comprises SEQ ID NO:9
set forth in U.S. Ser. No. 12/269,824 and the nucleic acid sequence
that encodes an influenza A hemaggultinin H3 comprises SEQ ID NO:11
set forth in U.S. Ser. No. 12/269,824.
22. The composition of claim 20 comprising: a nucleic acid molecule
comprising SEQ ID NO:9; a nucleic acid molecule comprising SEQ ID
NO:13; and a nucleic acid molecule that encodes an influenza A
hemaggultinin H3 comprising SEQ ID NO:11 set forth in U.S. Ser. No.
12/269,824.
23. The composition of claim 22 wherein the nucleic acid molecule
comprising SEQ ID NO:9 is a plasmid; the nucleic acid molecule
comprising SEQ ID NO:13 is a plasmid; and the nucleic acid molecule
that encodes an influenza A hemaggultinin H3 comprising SEQ ID
NO:11 set forth in U.S. Ser. No. 12/269,824 is a plasmid.
24. A method of inducing an immune response comprising the step of
administering to an individual a nucleic acid molecule comprising
nucleic acid sequence of claim 1.
25. A method of inducing an immune response comprising the step of
administering to an individual a composition of claim 10.
26. A method of inducing an immune response comprising the step of
administering to an individual a composition of claim 23.
27. A method of protecting an individual against infection by a
swine origin human influenza A strain comprising the step of:
administering to said individual a prophylactically effective
amount of a nucleic acid molecule comprising nucleic acid sequence
selected from the group consisting of: SEQ ID NO:1, a nucleic acid
sequence 95% homologous to SEQ ID NO:1; a fragment of SEQ ID NO:1,
a nucleic acid sequence 95% homologous to a fragment of SEQ ID
NO:1; SEQ ID NO:9, a nucleic acid sequence 95% homologous to SEQ ID
NO:9; a fragment of SEQ ID NO:9, and a nucleic acid sequence 95%
homologous to a fragment of SEQ ID NO:9; wherein the nucleic acid
sequence is expressed in cells of said individual and a immune
response against said protein is induced that is a protective
immune response against swine origin human influenza A.
28. A method of protecting an individual against infection by a
swine origin human influenza A strain comprising the step of:
administering to said individual a prophylactically effective
amount of a composition that comprises a) a first nucleic acid
sequence selected from the group consisting of: SEQ ID NO:1, a
nucleic acid sequence 95% homologous to SEQ ID NO:1; a fragment of
SEQ ID NO:1, a nucleic acid sequence 95% homologous to a fragment
of SEQ ID NO:1; SEQ ID NO:9, a nucleic acid sequence 95% homologous
to SEQ ID NO:9; a fragment of SEQ ID NO:9, and a nucleic acid
sequence 95% homologous to a fragment of SEQ ID NO:9; and b) one or
more additional nucleic acid sequences that encode one or more
proteins selected from the group consisting of one or more of: an
influenza A hemaggultinin H1, an influenza A hemaggultinin H2, an
influenza A hemaggultinin H3, influenza A H4 influenza A
hemaggultinin H5, an influenza A hemaggultinin H3, influenza A
hemaggultinin H5, influenza A N1 . . . influenza A hemaggultinin
H6, an influenza A hemaggultinin H7, influenza A hemaggultinin H5,
influenza A hemaggultinin H6, an influenza A hemaggultinin H7, an
influenza A hemaggultinin H8, an influenza A hemaggultinin H9, an
influenza A hemaggultinin H10, an influenza A hemaggultinin H11, an
influenza A hemaggultinin H12, influenza A H13 influenza A
hemaggultinin H14, an influenza A hemaggultinin H15, influenza A
hemaggultinin H16, an influenza A neuraminidase N1, an influenza A
neuraminidase N2, an influenza A neuraminidase N3, an influenza A
neuraminidase N4, an influenza A neuraminidase N5, an influenza A
neuraminidase N6, an influenza A neuraminidase N7, an influenza A
neuraminidase N8, an influenza A neuraminidase N9, an influenza B
hemaggultinin and an influenza B neuraminidase; wherein the first
nucleic acid sequence is expressed in cells of said individual and
an immune response against said first protein is induced that is a
protective immune response against swine origin human influenza A,
the one or more additional nucleic acid sequences are expressed in
cells of said individual and immune responses against said one or
more second proteins are induced.
29. The method of claim 28 wherein the composition comprises one or
more of: a nucleic acid sequence comprising SEQ ID NO:1; a nucleic
acid sequence comprising SEQ ID NO:9; a nucleic acid sequence
comprising SEQ ID NO:13; a nucleic acid sequence that encodes an
influenza A hemaggultinin H1; and a nucleic acid sequence that
encodes an influenza A hemaggultinin H3.
30. The method of claim 28 wherein the nucleic acid sequence that
encodes an influenza A hemaggultinin H1 comprises SEQ ID NO:9 set
forth in U.S. Ser. No. 12/269,824 and the nucleic acid sequence
that encodes an influenza A hemaggultinin H3 comprises SEQ ID NO:11
set forth in U.S. Ser. No. 12/269,824.
31. The method of claim 28 wherein the composition comprises one or
more of: a nucleic acid molecule comprising SEQ ID NO:9; a nucleic
acid molecule comprising SEQ ID NO:13; and a nucleic acid molecule
that encodes an influenza A hemaggultinin H3 comprising SEQ ID
NO:11 set forth in U.S. Ser. No. 12/269,824.
32. The method of claim 31 wherein the nucleic acid molecule
comprising SEQ ID NO:9 is a plasmid; the nucleic acid molecule
comprising SEQ ID NO:13 is a plasmid; and the nucleic acid molecule
that encodes an influenza A hemaggultinin H3 comprising SEQ ID
NO:11 set forth in U.S. Ser. No. 12/269,824 is a plasmid.
33. A method of treating an individual who has been infected by a
swine origin human influenza A strain comprising the step of:
administering to said individual a therapeutically effective amount
of a nucleic acid molecule comprising nucleic acid sequence
selected from the group consisting of: SEQ ID NO:1, a nucleic acid
sequence 95% homologous to SEQ ID NO:1; a fragment of SEQ ID NO:1,
a nucleic acid sequence 95% homologous to a fragment of SEQ ID
NO:1; SEQ ID NO:9, a nucleic acid sequence 95% homologous to SEQ ID
NO:9; a fragment of SEQ ID NO:9, and a nucleic acid sequence 95%
homologous to a fragment of SEQ ID NO:9; wherein the nucleic acid
sequence is expressed in cells of said individual and a immune
response against said protein is induced that is a protective
immune response against swine origin human influenza A.
34. A method of treating an individual who has been infected by a
swine origin human influenza A strain comprising the step of:
administering to said individual a therapeutically effective amount
of a composition that comprises a) a first nucleic acid sequence
selected from the group consisting of: SEQ ID NO:1, a nucleic acid
sequence 95% homologous to SEQ ID NO:1; a fragment of SEQ ID NO:1,
a nucleic acid sequence 95% homologous to a fragment of SEQ ID
NO:1; SEQ ID NO:9, a nucleic acid sequence 95% homologous to SEQ ID
NO:9; a fragment of SEQ ID NO:9, and a nucleic acid sequence 95%
homologous to a fragment of SEQ ID NO:9; and b) one or more
additional nucleic acid sequences that encode one or more proteins
selected from the group consisting of one or more of: an influenza
A hemaggultinin H1, an influenza A hemaggultinin H2, an influenza A
hemaggultinin H3, influenza A H4 influenza A hemaggultinin H5, an
influenza A hemaggultinin H3, influenza A hemaggultinin H5,
influenza. A N1 . . . influenza A hemaggultinin H6, an influenza A
hemaggultinin H7, influenza A hemaggultinin H5, influenza A
hemaggultinin H6, an influenza A hemaggultinin H7, an influenza A
hemaggultinin H8, an influenza A hemaggultinin H9, an influenza A
hemaggultinin H10, an influenza A hemaggultinin H11, an influenza A
hemaggultinin H12, influenza A H13 influenza A hemaggultinin H14,
an influenza A hemaggultinin H15, influenza A hemaggultinin H16, an
influenza A neuraminidase N1, an influenza A neuraminidase N2, an
influenza A neuraminidase N3, an influenza A neuraminidase N4, an
influenza A neuraminidase N5, an influenza A neuraminidase N6, an
influenza A neuraminidase N7, an influenza A neuraminidase N8, an
influenza A neuraminidase N9, an influenza B hemaggultinin and an
influenza B neuraminidase; wherein the first nucleic acid sequence
is expressed in cells of said individual and an immune response
against said first protein is induced that is a protective immune
response against swine origin human influenza A, the one or more
additional nucleic acid sequences are expressed in cells of said
individual and immune responses against said one or more second
proteins are induced.
35. The method of claim 34 wherein the composition comprises one or
more of: a nucleic acid sequence comprising SEQ ID NO:1; a nucleic
acid sequence comprising SEQ ID NO:9; a nucleic acid sequence
comprising SEQ ID NO:13; a nucleic acid sequence that encodes an
influenza A hemaggultinin H1; and a nucleic acid sequence that
encodes an influenza A hemaggultinin H3.
36. The method of claim 34 wherein the nucleic acid sequence that
encodes an influenza A hemaggultinin H1 comprises SEQ ID NO:9 set
forth in U.S. Ser. No. 12/269,824 and the nucleic acid sequence
that encodes an influenza A hemaggultinin H3 comprises SEQ ID NO:11
set forth in U.S. Ser. No. 12/269,824.
37. The method of claim 34 wherein the composition comprises one or
more of: a nucleic acid molecule comprising SEQ ID NO:9; a nucleic
acid molecule comprising SEQ ID NO:13; and a nucleic acid molecule
that encodes an influenza A hemaggultinin H3 comprising SEQ ID
NO:11 set forth in U.S. Ser. No. 12/269,824.
38. The method of claim 37 wherein the nucleic acid molecule
comprising SEQ ID NO:9 is a plasmid; the nucleic acid molecule
comprising SEQ ID NO:13 is a plasmid; and the nucleic acid molecule
that encodes an influenza A hemaggultinin H3 comprising SEQ ID
NO:11 set forth in U.S. Ser. No. 12/269,824 is a plasmid.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to improved influenza viral
vaccines, improved methods for inducing immune responses against
influenza, improved methods for diagnosing vaccinated vs. infected
influenza mammalian hosts and for prophylactically and/or
therapeutically immunizing individuals against influenza.
BACKGROUND OF THE INVENTION
[0002] Influenza, commonly referred to as the flu, is an infectious
disease caused by RNA viruses of the family Orthomyxoviridae.
Influenza or flu viruses infect birds and mammals. Three of the
five genera of Orthomyxoviridae are influenza viruses: Influenza A,
Influenza B and Influenza C. Of these, Influenza A is the most
common.
[0003] Influenza is typically transmitted through the air in
aerosols produced by coughs or sneezes and by direct contact with
body fluids containing the virus or contaminated surfaces. Seasonal
epidemics of influenza occur worldwide and result in hundreds of
thousands of deaths annually. In some years, pandemics occur and
cause millions of deaths. In addition, livestock, particularly
poultry and swine, are also susceptible to annual epidemics and
occasional pandemics which cause large numbers of animal deaths and
monetary losses.
[0004] Structurally, influenza viruses are similar, having
generally spherical or filamentous virus particles of about 80-120
nm made up of similar molecular component. A central core
comprising viral proteins and viral RNA is covered by a viral
envelope made up of two different glycoproteins and a lipid coat
derived from the cell that the viral particle is produced in. Two
additional different glycoproteins are anchored within the viral
envelope and include portions which project outward on the
surface.
[0005] The influenza virus RNA genome is typically provided as
eight different single stranded, negative sense RNA segments that
together make up the genome's eleven viral genes which encode the
eleven proteins (HA, NA, NP, M1, M2, NS1, NEP, PA, PB1, PB1-F2,
PB2). The eight RNA segments are: 1) HA, which encodes
hemagglutinin (about 500 molecules of hemagglutinin are needed to
make one virion); 2) NA, which encodes neuraminidase (about 100
molecules of neuraminidase are needed to make one virion); 3) NP,
which encodes nucleoprotein; 4) M, which encodes two matrix
proteins (the M1 and the M2) by using different reading frames from
the same RNA segment (about 3000 matrix protein molecules are
needed to make one virion); 5) NS, which encodes two distinct
non-structural proteins (NS1 and NEP) by using different reading
frames from the same RNA segment; 6) PA, which encodes an RNA
polymerase; 7) PB1, which encodes an RNA polymerase and PB1-F2
protein (induces apoptosis) by using different reading frames from
the same RNA segment; and 8) PB2, which encodes an RNA
polymerase.
[0006] Of these eleven proteins, hemagglutinin (HA) and
neuraminidase (NA) are two large glycoproteins anchored in the
viral envelope and present on the outer surface of the viral
particles. These proteins serve as immunogens for immune responses
against influenza. HA, which is a lectin that mediates binding of
the virus to target cells and entry of the viral genome into the
target cell, is expressed as a single gene product, HA0, and later
processed by host proteases to produce two subunits, HA1 and HA2,
which together form a complex on the surface of influenza viral
particles. NA is involved in the release of newly produced mature
viral particles produced in infected cells.
[0007] There are sixteen known HA serotypes and nine known NA
serotypes for Influenza A viruses. The identity of the different
serotypes present in a viral particle typically is used to describe
a virus. For example, H1N1 is an influenza virus with HA serotype
H1 and NA serotype N1; H5N1 is an influenza virus with HA serotype
H5 and NA serotype N1. Only H1, H2 and H3 serotypes, and N1 and N2
serotypes usually infect humans.
[0008] Influenza strains are generally species or genus specific;
i.e. an influenza strain which can infect pigs (a swine influenza
virus) typically does not infect humans or birds; an influenza
strain which can infect birds (an avian influenza virus) does not
infect humans or pigs; and an influenza strain which can infect
humans (a human influenza virus) does not infect birds or pigs.
Influenza strains, however, can mutate and become infective from
one species to another. For example, a strain which only infects
pigs, a swine influenza, can mutate or recombine to become a strain
that can infect humans only or both pigs and humans. A flu virus
commonly referred to as "swine flu" is an influenza virus strain,
such as an H1N1 strain, which can infect humans and which was
derived from a strain that was previously specific for pigs (i.e. a
swine flu virus is a swine origin human influenza or swine derived
human influenza). A flu virus commonly referred to as "bird flu" is
an influenza virus strain, such as an H5N1 strain, which can infect
humans and which was derived from a strain that was previously
specific for birds (i.e. a bird flu virus avian origin human
influenza or avian derived human influenza).
[0009] Vaccinations against influenza are provided seasonally to
many humans in developed countries and sometime to livestock. The
vaccines used are limited in their protective results because the
immune responses induced by the vaccines are specific for certain
subtypes of virus. Different influenza vaccines are developed and
administered annually based upon international surveillance and
scientists' estimations of which types and strains of viruses will
circulate in a given year. The virus changes significantly by
mutation, recombination and reassortment of the segments. Thus,
vaccines given in one year are not considered protective against
the seasonal strains that are widely transmitted the following
year.
[0010] The "flu shot" commonly promoted U.S. Centers for Disease
Control and Prevention usually contains three killed/inactivated
influenza viruses: one A (H3N2) virus, one A (H1N1) virus, and one
B virus. Thus, it is apparent that vaccinations are limited to
predictions of subtypes, and the availability of a specific vaccine
to that subtype.
[0011] The direct administration of nucleic acid sequences to
vaccinate against animal and human diseases has been studied and
much effort has focused on effective and efficient means of nucleic
acid delivery in order to yield necessary expression of the desired
antigens, resulting immunogenic response and ultimately the success
of this technique.
[0012] DNA vaccines have many conceptual advantages over more
traditional vaccination methods, such as live attenuated viruses
and recombinant protein-based vaccines. DNA vaccines are safe,
stable, easily produced, and well tolerated in humans with
preclinical trials indicating little evidence of plasmid
integration [Martin, T., et al., Plasmid DNA malaria vaccine: the
potential for genomic integration after intramuscular injection.
Hum Gene Ther, 1999. 10 (5): p. 759-68; Nichols, W. W., et al.,
Potential DNA vaccine integration into host cell genome. Ann N Y
Acad Sci, 1995. 772: p. 30-9]. In addition, DNA vaccines are well
suited for repeated administration due to the fact that efficacy of
the vaccine is not influenced by pre-existing antibody titers to
the vector [Chattergoon, M., J. Boyer, and D. B. Weiner, Genetic
immunization: a new era in vaccines and immune therapeutics. FASEB
3, 1997. 11 (10): p. 753-63]. However, one major obstacle for the
clinical adoption of DNA vaccines has been a decrease in the
platform's immunogenicity when moving to larger animals [Liu, M. A.
and J. B. Ulmer, Human clinical trials of plasmid DNA vaccines. Adv
Genet, 2005. 55: p. 25-40]. Recent technological advances in the
engineering of DNA vaccine immunogen, such has codon optimization,
RNA optimization and the addition of immunoglobulin leader
sequences have improved expression and immunogenicity of DNA
vaccines [Andre, S., et al., Increased immune response elicited by
DNA vaccination with a synthetic gp120 sequence with optimized
codon usage. J Viral, 1998. 72 (2): p. 1497-503; Deml, L., et al.,
Multiple effects of codon usage optimization on expression and
immunogenicity of DNA candidate vaccines encoding the human
immunodeficiency virus type 1 Gag protein. J Virol, 2001. 75 (22):
p. 10991-1001; Laddy, D. J., et al., Immunogenicity of novel
consensus-based DNA vaccines against avian influenza. Vaccine,
2007. 25 (16): p. 2984-9; Frelin, L., et al., Codon optimization
and mRNA amplification effectively enhances the immunogenicity of
the hepatitis C virus nonstructural 3/4A gene. Gene Ther, 2004. 11
(6): p. 522-33], as well as, recently developed technology in
plasmid delivery systems such as electroporation [Hirao, L. A., et
al., Intradermal/subcutaneous immunization by electroporation
improves plasmid vaccine delivery and potency in pigs and rhesus
macaques. Vaccine, 2008. 26 (3): p. 440-8; Luckay, A., et al.,
Effect of plasmid DNA vaccine design and in vivo electroporation on
the resulting vaccine-specific immune responses in rhesus macaques.
J Viral, 2007. 81 (10): p. 5257-69; Ahlen, G., et al., In vivo
electroporation enhances the immunogenicity of hepatitis C virus
nonstructural 3/4A DNA by increased local DNA uptake, protein
expression, inflammation, and infiltration of CD3+ T cells. J
Immunol, 2007. 179 (7): p. 4741-53]. In addition, studies have
suggested that the use of consensus immunogens can be able to
increase the breadth of the cellular immune response as compared to
native antigens alone [Yan, J., et al., Enhanced cellular immune
responses elicited by an engineered HIV-1 subtype B consensus-based
envelope DNA vaccine. Mol Ther, 2007. 15 (2): p. 411-21; Rolland,
M., et al., Reconstruction and function of ancestral center-of-tree
human immunodeficiency virus type 1 proteins. J Virol, 2007. 81
(16): p. 8507-14].
[0013] One method for delivering nucleic acid sequences such as
plasmid DNA is the electroporation (EP) technique. The technique
has been used in human clinical trials to deliver anti-cancer
drugs, such as bleomycin, and in many preclinical studies on a
large number of animal species.
[0014] There remains a need for an immunogenic influenza consensus
hemagglutinin protein, for nucleic acid constructs that encode such
a protein and for compositions useful to induce immune responses
against multiple strains of influenza. There remains a need for
effective vaccines against influenza that are economical and
effective across numerous influenza subtypes for treating
individuals.
SUMMARY OF THE INVENTION
[0015] Provided herein are isolated nucleic acid molecules
comprising a nucleic acid sequence selected from the group
consisting of SEQ ID NO:1, a nucleic acid sequence that is 95%
homologous to SEQ ID NO:1; a fragment of SEQ ID NO:1; a nucleic
acid sequence that is 95% homologous to a fragment of SEQ ID NO:1;
SEQ ID NO:3; a nucleic acid sequence that is 95% homologous to SEQ
ID NO:3; a fragment of SEQ ID NO:3; a nucleic acid sequence that is
95% homologous to a fragment of SEQ ID NO:3; SEQ ID NO:6; a nucleic
acid sequence that is 95% homologous to SEQ ID NO:6; a fragment of
SEQ ID NO:6; a nucleic acid sequence that is 95% homologous to a
fragment of SEQ ID NO:6; SEQ ID NO:9, a nucleic acid sequence that
is 95% homologous to SEQ ID NO:9; a fragment of SEQ ID NO:9; a
nucleic acid sequence that is 95% homologous to a fragment of SEQ
ID NO:9; SEQ ID NO:11, a nucleic acid sequence that is 95%
homologous to SEQ ID NO:11; a fragment of SEQ ID NO:11; a nucleic
acid sequence that is 95% homologous to a fragment of SEQ ID NO:11;
SEQ ID NO:13; a nucleic acid sequence that is 95% homologous to SEQ
ID NO:13; a fragment of SEQ ID NO:13; a nucleic acid sequence that
is 95% homologous to a fragment of SEQ ID NO:13; and SEQ ID NO:15;
a nucleic acid sequence that is 95% homologous to SEQ ID NO:15; a
fragment of SEQ ID NO:15; a nucleic acid sequence that is 95%
homologous to a fragment of SEQ ID NO:15.
[0016] Also provided are compositions comprising: a) a first
nucleic acid sequence selected from the group consisting of one or
more of SEQ ID NO:1, a nucleic acid sequence that is 95% homologous
to SEQ ID NO:1; a fragment of SEQ ID NO:1; a nucleic acid sequence
that is 95% homologous to a fragment of SEQ ID NO:1; SEQ ID NO:3; a
nucleic acid sequence that is 95% homologous to SEQ ID NO:3; a
fragment of SEQ ID NO:3; a nucleic acid sequence that is 95%
homologous to a fragment of SEQ ID NO:3; SEQ ID NO:6; a nucleic
acid sequence that is 95% homologous to SEQ ID NO:6; a fragment of
SEQ ID NO:6; a nucleic acid sequence that is 95% homologous to a
fragment of SEQ ID NO:6; SEQ ID NO:9; a nucleic acid sequence that
is 95% homologous to SEQ ID NO:9; a fragment of SEQ ID NO:9; a
nucleic acid sequence that is 95% homologous to a fragment of SEQ
ID NO:9; SEQ ID NO:11; a nucleic acid sequence that is 95%
homologous to SEQ ID NO:11; a fragment of SEQ ID NO:11; and a
nucleic acid sequence that is 95% homologous to a fragment of SEQ
ID NO:11 SEQ ID NO:13; a nucleic acid sequence that is 95%
homologous to SEQ ID NO:13; a fragment of SEQ ID NO:13; a nucleic
acid sequence that is 95% homologous to a fragment of SEQ ID NO:13;
SEQ ID NO:15; a nucleic acid sequence that is 95% homologous to SEQ
ID NO:15; a fragment of SEQ ID NO:15; and a nucleic acid sequence
that is 95% homologous to a fragment of SEQ ID NO:15; and b) a
second nucleic acid sequence that encodes a protein selected from
the group consisting of one or more of: influenza A H1, H2, H3, H4,
H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, N1, N2, N3,
N4, N5, N6, N7, N8, N9, influenza B hemagglutinin, neuraminidase
and fragments thereof.
[0017] Some aspects of the invention provide methods of inducing an
immune response comprising the step of: administering to an
individual such nucleic acid molecules and/or compositions.
[0018] Additional aspects of the invention provide methods of
protecting an individual against infection. The methods comprise
the step of: administering to said individual a prophylactically
effective amount of a nucleic acid molecule comprising such nucleic
acid sequence or compositions; wherein the nucleic acid sequence is
expressed in cells of said individual and a protective immune
response is induced against a protein encoded by said nucleic acid
sequence. In some embodiment, the immune response is a protective
immune response against swine origin human influenza.
[0019] In some aspects of the invention, methods are provided for
treating an individual who has been infected by Influenza. The
methods comprise the step of: administering to said individual a
therapeutically effective amount of such nucleic acid molecules
and/or composition. In some embodiment, the immune response is a
therapeutic immune response against swine origin human
influenza.
BRIEF DESCRIPTION OF THE FIGURES
[0020] FIG. 1 is a map of the 2999 basepair backbone vector plasmid
pVAX1 (Invitrogen, Carlsbad Calif.). The CMV promoter is located at
bases 137-724. The T7 promoter/priming site is at bases 664-683.
Multiple cloning sites are at bases 696-811. Bovine GH
polyadenylation signal is at bases 829-1053. The Kanamycin
resistance gene is at bases 1226-2020. The pUC origin is at bases
2320-2993.
[0021] Based upon the sequence of pVAX1 available from Invitrogen,
the following mutations were found in the sequence of pVAX1 that
was used as the backbone for pGX2009:
[0022] C>G 241 in CMV promoter
[0023] C>T 1942 backbone, downstream of the bovine growth
hormone polyadenylation signal (bGHpolyA)
[0024] A>- 2876 backbone, downstream of the Kanamycin gene
[0025] C>T 3277 in pUC origin of replication (Ori) high copy
number mutation (see Nucleic Acid Research 1985)
[0026] G>C 3753 in very end of pUC On upstream of RNASeH
site
[0027] Base pairs 2, 3 and 4 are changed from ACT to CTG in
backbone, upstream of CMV promoter.
[0028] FIG. 2 shows two maps of the plasmid pGX2009, which is also
referred to as pH1HA09. The nucleic acid sequence of the plasmid
pGX2009 (SEQ ID NO:5) includes the coding sequence for the
consensus H1 protein construct (amino acid SEQ ID NO:4 encoded by
SEQ ID NO:3) which includes the IgE leader (amino acid SEQ ID
NO:17) linked to the N terminal of the consensus H1 amino acid
sequence (amino acid SEQ ID NO:2 encoded by SEQ ID NO:1) which is
linked at its C terminal to the HA Tag (SEQ ID NO:18). The
consensus H1 protein (amino acid SEQ ID NO:4 encoded by SEQ ID
NO:3) is labeled SwiHum Con HA and H1HA09.
[0029] FIG. 3 shows a maps of the plasmid pGX2006. The nucleic acid
sequence of the plasmid pGX2006 (SEQ ID NO:8) includes the coding
sequence for consensus H2 protein (amino acid SEQ ID NO:7 encoded
by SEQ ID NO:6) which is labeled H2HA.
[0030] FIG. 4 shows data from hemagglutination inhibition assays
performed with sera from immunized ferrets.
[0031] FIG. 5 shows results of a challenge of immunized and
unimmunized ferrets with a novel H1N1 strain.
DETAILED DESCRIPTION
[0032] Consensus amino acid sequences of each of influenza A H1 and
H2 (referred to herein as "consensus H1" (SEQ ID NO:2) and
"consensus H2" (SEQ ID NO:7), respectively), as well as a novel
synthetic hybrid consensus H1 influenza A hemagglutinin amino acid
sequence (referred to herein as "consensus U2" (SEQ ID NO:10)) and
a consensus amino acid sequence of influenza B hemagglutinin
(referred to herein as "consensus BHA" (SEQ ID NO:13)) are
provided, which can provide protection of mammals against
influenza. In addition, proteins are provided which comprise the
consensus H1 amino acid sequence, the consensus H2 amino acid
sequence, the consensus U2 amino acid sequence and/or the consensus
BHA amino acid sequence. In some aspects, nucleic acid sequences
are provided which encode proteins comprising the consensus H1
amino acid sequence (for example (SEQ ID NO:1) or (SEQ ID NO:3)),
the consensus H2 amino acid sequence (for example (SEQ ID NO:6)),
the consensus U2 amino acid sequence (for example (SEQ ID NO:9) or
(SEQ ID NO:11)), and/or the consensus BHA amino acid sequence (for
example (SEQ ID NO:13) or (SEQ ID NO:15)).
[0033] While not being bound by scientific theory, a vaccine that
can be used to elicit an immune response (humoral, cellular, or
both) broadly against multiple influenza subtypes may comprise one
or more of the following: 1) a nucleic acid sequence that encodes a
protein comprising the consensus H1 amino acid sequence; 2) a
protein comprising the consensus H1 amino acid sequence; 3) a
nucleic acid sequence that encodes a protein comprising the
consensus H2 amino acid sequence; 4) a protein comprising the
consensus H2 amino acid sequence; 5) a nucleic acid sequence that
encodes a protein comprising the consensus U2 amino acid sequence;
6) a protein comprising the consensus U2 amino acid sequence; 7) a
nucleic acid sequence that encodes a protein comprising the
consensus BHA amino acid sequence; and 8) a protein comprising the
consensus BHA amino acid sequence.
[0034] Immunization methods can be performed and vaccines can be
prepared which use and/or combine two or more of the following
components: 1) a nucleic acid sequence that encodes a protein
comprising the consensus H1 amino acid sequence; 2) a protein
comprising the consensus H1 amino acid sequence; 3) a nucleic acid
sequence that encodes a protein comprising the consensus H2 amino
acid sequence, 4) a protein comprising the consensus H2 amino acid
sequence; 5) a nucleic acid sequence that encodes a protein
comprising the consensus U2 amino acid sequence, 6) a protein
comprising the consensus U2 amino acid sequence, 7) a nucleic acid
sequence that encodes a protein comprising the consensus BHA amino
acid sequence, and 8) a protein comprising the consensus BHA amino
acid sequence. For more broad based treatments against influenza,
immunization methods can be performed and vaccines can be prepared
which use and/or combine one or more other influenza proteins such
as influenza A H1-H16, influenza A N1-N9, influenza B
hemagglutinin, influenza B neuraminidase and/or genes encoding
these proteins together with one or more of the following
components: 1) a nucleic acid sequence that encodes a protein
comprising the consensus H1 amino acid sequence; 2) a protein
comprising the consensus H1 amino acid sequence; 3) a nucleic acid
sequence that encodes a protein comprising the consensus H2 amino
acid sequence, 4) a protein comprising the consensus H2 amino acid
sequence; 5) a nucleic acid sequence that encodes a protein
comprising the consensus U2 amino acid sequence, 6) a protein
comprising the consensus U2 amino acid sequence, 7) a nucleic acid
sequence that encodes a protein comprising the consensus BHA amino
acid sequence, and 8) a protein comprising the consensus BHA amino
acid sequence.
1. Definitions
[0035] The terminology used herein is for the purpose of describing
particular embodiments only and is not intended to be limiting. As
used in the specification and the appended claims, the singular
forms "a," "an" and "the" include plural referents unless the
context clearly dictates otherwise.
[0036] For recitation of numeric ranges herein, each intervening
number there between with the same degree of precision is
explicitly contemplated. For example, for the range of 6-9, the
numbers 7 and 8 are contemplated in addition to 6 and 9, and for
the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6,
6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
[0037] a. Adjuvant
[0038] "Adjuvant" as used herein means any molecule added to the
DNA plasmid vaccines described herein to enhance the immunogenicity
of the antigens encoded by the DNA plasmids and the encoding
nucleic acid sequences described hereinafter.
[0039] b. Antibody
[0040] "Antibody" as used herein means an antibody of classes IgG,
IgM, IgA, IgD or IgE, or fragments, fragments or derivatives
thereof, including Fab, F(ab)2, Fd, and single chain antibodies,
diabodies, bispecific antibodies, bifunctional antibodies and
derivatives thereof. The antibody can be an antibody isolated from
the serum sample of mammal, a polyclonal antibody, affinity
purified antibody, or mixtures thereof which exhibits sufficient
binding specificity to a desired epitope or a sequence derived
therefrom.
[0041] c. Coding Sequence
[0042] "Coding sequence" or "encoding nucleic acid" as used herein
means the nucleic acids (RNA or DNA molecule) that comprise a
nucleotide sequence which encodes a protein. The coding sequence
can further include initiation and termination signals operably
linked to regulatory elements including a promoter and
polyadenylation signal capable of directing expression in the cells
of an individual or mammal to whom the nucleic acid is
administered.
[0043] d. Complement
[0044] "Complement" or "complementary" as used herein means a
nucleic acid can mean Watson-Crick (e.g., A-T/U and C-G) or
Hoogsteen base pairing between nucleotides or nucleotide analogs of
nucleic acid molecules.
[0045] e. Consensus or Consensus Sequence
[0046] "Consensus" or "consensus sequence" as used herein means a
polypeptide sequence based on analysis of an alignment of multiple
subtypes of a particular influenza antigen. Nucleic acid sequences
that encode a consensus polypeptide sequence may be prepared.
Vaccines comprising proteins that comprise consensus sequences
and/or nucleic acid molecules that encode such proteins can be used
to induce broad immunity against multiple subtypes or serotypes of
a particular influenza antigen. Consensus influenza antigens can
include influenza A consensus hemagglutinin amino acid sequences,
including for example consensus H1, consensus H2, or influenza B
consensus hemagglutinin amino acid sequences.
[0047] f. Constant Current
[0048] "Constant current" as used herein means a current that is
received or experienced by a tissue, or cells defining said tissue,
over the duration of an electrical pulse delivered to same tissue.
The electrical pulse is delivered from the electroporation devices
described herein. This current remains at a constant amperage in
said tissue over the life of an electrical pulse because the
electroporation device provided herein has a feedback element,
preferably having instantaneous feedback. The feedback element can
measure the resistance of the tissue (or cells) throughout the
duration of the pulse and cause the electroporation device to alter
its electrical energy output (e.g., increase voltage) so current in
same tissue remains constant throughout the electrical pulse (on
the order of microseconds), and from pulse to pulse. In some
embodiments, the feedback element comprises a controller.
[0049] g. Current Feedback or Feedback
[0050] "Current feedback" or "feedback" can be used interchangeably
and means the active response of the provided electroporation
devices, which comprises measuring the current in tissue between
electrodes and altering the energy output delivered by the EP
device accordingly in order to maintain the current at a constant
level. This constant level is preset by a user prior to initiation
of a pulse sequence or electrical treatment. The feedback can be
accomplished by the electroporation component, e.g., controller, of
the electroporation device, as the electrical circuit therein is
able to continuously monitor the current in tissue between
electrodes and compare that monitored current (or current within
tissue) to a preset current and continuously make energy-output
adjustments to maintain the monitored current at preset levels. The
feedback loop can be instantaneous as it is an analog closed-loop
feedback.
[0051] h. Decentralized Current
[0052] "Decentralized current" as used herein means the pattern of
electrical currents delivered from the various needle electrode
arrays of the electroporation devices described herein, wherein the
patterns minimize, or preferably eliminate, the occurrence of
electroporation related heat stress on any area of tissue being
electroporated.
[0053] i. Electroporation
[0054] "Electroporation," "electro-permeabilization," or
"electro-kinetic enhancement" ("EP") as used interchangeably herein
means the use of a transmembrane electric field pulse to induce
microscopic pathways (pores) in a bio-membrane; their presence
allows biomolecules such as plasmids, oligonucleotides, siRNA,
drugs, ions, and water to pass from one side of the cellular
membrane to the other.
[0055] j. Feedback Mechanism
[0056] "Feedback mechanism" as used herein means a process
performed by either software or hardware (or firmware), which
process receives and compares the impedance of the desired tissue
(before, during, and/or after the delivery of pulse of energy) with
a present value, preferably current, and adjusts the pulse of
energy delivered to achieve the preset value. A feedback mechanism
can be performed by an analog closed loop circuit.
[0057] k. Fragment
[0058] "Fragment" as used herein with respect to nucleic acid
sequences means a nucleic acid sequence or a portion thereof, that
encodes a polypeptide capable of eliciting an immune response in a
mammal that cross reacts with a full length wild type strain
influenza antigen, including, e.g., an influenza A H1
hemagglutinin, an influenza A H2 hemagglutinin or an influenza B
hemagglutinin. The fragments can be DNA fragments selected from at
least one of the various nucleotide sequences that encode the
consensus amino acid sequences and constructs comprising such
sequences, including SEQ ID NOS: 1, 3, 6, 9, 11 13 and 15. DNA
fragments can comprise coding sequences for the immunoglobulin
leader such as IgE or IgG sequences. The DNA fragments can be 30 or
more nucleotides in length, 45 or more, 60 or more, 75 or more, 90
or more, 120 or more, 150 or more, 180 or more, 210 or more, 240 or
more, 270 or more, 300 or more, 360 or more, 420 or more, 480 or
more, 540 or more, 600 or more, 660 or more, 720 or more, 780 or
more, 840 or more, 900 or more, 960 or more, 1020 or more, 1080 or
more, 1140 or more, 1200 or more, 1260 or more, 1320 or more, 1380
or more, 1440 or more, 1500 or more, 1560 or more, 1620 or more,
1680 or more, 1740 or more, 1800 or more, 1860 or more, 1820 or
more, 1880 or more, 1940 or more, 2000 or more, 2600 or more, 2700
or more, 2800 or more, 2900 or more, 2910 or more, 2920 or more,
2930 or more, 2931 or more, 2932 or more, 2933 or more, 2934 or
more, 2935 or more, 2936 or more, 2937 or more, or 2938 or more in
length. DNA fragments can be fewer than 10 nucleotides, fewer than
20, fewer than 30, fewer than 40, fewer than 50, fewer than 60,
fewer than 75, fewer than 90, fewer than 120, fewer than 150, fewer
than 180, fewer than 210, fewer than 240, fewer than 270, fewer
than 300, fewer than 360, fewer than 420, fewer than 480, fewer
than 540, fewer than 600, fewer than 660, fewer than 720, fewer
than 780, fewer than 840, fewer than 900, fewer than 960, fewer
than 1020, fewer than 1080, fewer than 1140, fewer than 1200, fewer
than 1260, fewer than 1320, fewer than 1380, fewer than 1440, fewer
than 1500, fewer than 1560, fewer than 1620, fewer than 1680, or
fewer than 1740 nucleotides, fewer than 1800, fewer than 1860,
fewer than 1820, fewer than 1880, fewer than 1940, fewer than 2000,
fewer than 2600, fewer than 2700, fewer than 2800, fewer than 2900,
fewer than 2910, fewer than 2920, fewer than 2930, fewer than 2931,
fewer than 2932, fewer than 2933, fewer than 2934, fewer than 2935,
fewer than 2936, fewer than 2937, or fewer than 2938.
[0059] "Fragment" with respect to polypeptide sequences means a
polypeptide capable of eliciting an immune response in a mammal
that cross reacts with a full length wild type strain influenza
antigen, including, e.g., an influenza A H1 hemagglutinin, an
influenza A H2 hemagglutinin or an influenza B hemagglutinin. The
fragment can be polypeptide fragment selected from at least one of
the various polypeptide sequences of the present invention,
including SEQ ID NOS: 2, 4, 7, 10, 12, 14 and 16. Polypeptide
fragments can be analyzed to contact at least one antigenic epitope
as provided by a publicly available database such as the Los Alamos
National Laboratory's HA Sequence Database. Polypeptides HA
fragments can further comprise amino acid sequences for the
immunoglobulin leader such as IgE or IgG. The polypeptide fragments
can be 30 or more amino acids in length, 45 or more, 60 or more, 75
or more, 90 or more, 120 or more, 150 or more, 180 or more, 210 or
more, 240 or more, 270 or more, 300 or more, 360 or more, 420 or
more, 480 or more, 540 or more, 600 or more, 660 or more, or 710
amino acids or more in length. Polypeptide fragments can be fewer
than 10 amino acids, fewer than 20, fewer than 30, fewer than 40,
fewer than 50, fewer than 60, fewer than 75, fewer than 90, fewer
than 120, fewer than 150, fewer than 180, fewer than 210, fewer
than 240, fewer than 270, fewer than 300, fewer than 360, fewer
than 420, fewer than 480, fewer than 540, fewer than 600, fewer
than 660, fewer than 700, fewer than 701, fewer than 702, fewer
than 703, fewer than 704, fewer than 705, fewer than 706, fewer
than 707, fewer than 708, fewer than 709, or fewer than 710 amino
acids in length.
[0060] l. Genetic Construct
[0061] As used herein, the term "genetic construct" refers to the
DNA or RNA molecules that comprise a nucleotide sequence which
encodes a protein. The coding sequence includes initiation and
termination signals operably linked to regulatory elements
including a promoter and polyadenylation signal capable of
directing expression in the cells of the individual to whom the
nucleic acid molecule is administered. As used herein, the term
"expressible form" refers to gene constructs that contain the
necessary regulatory elements operable linked to a coding sequence
that encodes a protein such that when present in the cell of the
individual, the coding sequence will be expressed.
[0062] m. Identical
[0063] "Identical" or "identity" as used herein in the context of
two or more nucleic acids or polypeptide sequences, means that the
sequences have a specified percentage of residues that are the same
over a specified region. The percentage can be calculated by
optimally aligning the two sequences, comparing the two sequences
over the specified region, determining the number of positions at
which the identical residue occurs in both sequences to yield the
number of matched positions, dividing the number of matched
positions by the total number of positions in the specified region,
and multiplying the result by 100 to yield the percentage of
sequence identity. In cases where the two sequences are of
different lengths or the alignment produces one or more staggered
ends and the specified region of comparison includes only a single
sequence, the residues of single sequence are included in the
denominator but not the numerator of the calculation. When
comparing DNA and RNA, thymine (T) and uracil (U) can be considered
equivalent. Identity can be performed manually or by using a
computer sequence algorithm such as BLAST or BLAST 2.0.
[0064] n. Impedance
[0065] "Impedance" can be used when discussing the feedback
mechanism and can be converted to a current value according to
Ohm's law, thus enabling comparisons with the preset current.
[0066] o. Immune Response
[0067] "Immune response" as used herein means the activation of a
host's immune system, e.g., that of a mammal, in response to the
introduction of antigen such as an influenza hemagglutinin
consensus antigen. The immune response can be in the form of a
cellular or humoral response, or both.
[0068] p. Nucleic Acid
[0069] "Nucleic acid" or "oligonucleotide" or "polynucleotide" as
used herein means at least two nucleotides covalently linked
together. The depiction of a single strand also defines the
sequence of the complementary strand. Thus, a nucleic acid also
encompasses the complementary strand of a depicted single strand.
Many variants of a nucleic acid can be used for the same purpose as
a given nucleic acid. Thus, a nucleic acid also encompasses
substantially identical nucleic acids and complements thereof. A
single strand provides a probe that can hybridize to a target
sequence under stringent hybridization conditions. Thus, a nucleic
acid also encompasses a probe that hybridizes under stringent
hybridization conditions.
[0070] Nucleic acids can be single stranded or double stranded, or
can contain portions of both double stranded and single stranded
sequence. The nucleic acid can be DNA, both genomic and cDNA, RNA,
or a hybrid, where the nucleic acid can contain combinations of
deoxyribo- and ribo-nucleotides, and combinations of bases
including uracil, adenine, thymine, cytosine, guanine, inosine,
xanthine hypoxanthine, isocytosine and isoguanine. Nucleic acids
can be obtained by chemical synthesis methods or by recombinant
methods.
[0071] q. Operably Linked
[0072] "Operably linked" as used herein means that expression of a
gene is under the control of a promoter with which it is spatially
connected. A promoter can be positioned 5' (upstream) or 3'
(downstream) of a gene under its control. The distance between the
promoter and a gene can be approximately the same as the distance
between that promoter and the gene it controls in the gene from
which the promoter is derived. As is known in the art, variation in
this distance can be accommodated without loss of promoter
function.
[0073] r. Promoter
[0074] "Promoter" as used herein means a synthetic or
naturally-derived molecule which is capable of conferring,
activating or enhancing expression of a nucleic acid in a cell. A
promoter can comprise one or more specific transcriptional
regulatory sequences to further enhance expression and/or to alter
the spatial expression and/or temporal expression of same. A
promoter can also comprise distal enhancer or repressor elements,
which can be located as much as several thousand base pairs from
the start site of transcription. A promoter can be derived from
sources including viral, bacterial, fungal, plants, insects, and
animals. A promoter can regulate the expression of a gene component
constitutively, or differentially with respect to cell, the tissue
or organ in which expression occurs or, with respect to the
developmental stage at which expression occurs, or in response to
external stimuli such as physiological stresses, pathogens, metal
ions, or inducing agents. Representative examples of promoters
include the bacteriophage T7 promoter, bacteriophage T3 promoter,
SP6 promoter, lac operator-promoter, tac promoter, SV40 late
promoter, SV40 early promoter, RSV-LTR promoter, CMV IE promoter,
SV40 early promoter or SV40 late promoter and the CMV IE
promoter.
[0075] s. Stringent Hybridization Conditions
[0076] "Stringent hybridization conditions" as used herein means
conditions under which a first nucleic acid sequence (e.g., probe)
will hybridize to a second nucleic acid sequence (e.g., target),
such as in a complex mixture of nucleic acids. Stringent conditions
are sequence-dependent and will be different in different
circumstances. Stringent conditions can be selected to be about
5-10.degree. C. lower than the thermal melting point (T.sub.m) for
the specific sequence at a defined ionic strength pH. The T.sub.m
can be the temperature (under defined ionic strength, pH, and
nucleic concentration) at which 50% of the probes complementary to
the target hybridize to the target sequence at equilibrium (as the
target sequences are present in excess, at T.sub.m, 50% of the
probes are occupied at equilibrium). Stringent conditions can be
those in which the salt concentration is less than about 1.0 M
sodium ion, such as about 0.01-1.0 M sodium ion concentration (or
other salts) at pH 7.0 to 8.3 and the temperature is at least about
30.degree. C. for short probes (e.g., about 10-50 nucleotides) and
at least about 60.degree. C. for long probes (e.g., greater than
about 50 nucleotides). Stringent conditions can also be achieved
with the addition of destabilizing agents such as formamide. For
selective or specific hybridization, a positive signal can be at
least 2 to 10 times background hybridization. Exemplary stringent
hybridization conditions include the following: 50% formamide,
5.times.SSC, and 1% SDS, incubating at 42.degree. C., or,
5.times.SSC, 1% SDS, incubating at 65.degree. C., with wash in
0.2.times.SSC, and 0.1% SDS at 65.degree. C.
[0077] t. Substantially Complementary
[0078] "Substantially complementary" as used herein means that a
first sequence is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,
97%, 98% or 99% identical to the complement of a second sequence
over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 100, 180, 270, 360, 450, 540, 630, 720, 810, 900, 990,
1080, 1170, 1260, 1350, 1440, 1530, 1620, 1710, 1800, 1890, 1980,
2070 or more nucleotides or amino acids, or that the two sequences
hybridize under stringent hybridization conditions.
[0079] u. Substantially Identical
[0080] "Substantially identical" as used herein means that a first
and second sequence are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, 97%, 98% or 99% identical over a region of 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45,
50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 180, 270, 360, 450,
540, 630, 720, 810, 900, 990, 1080, 1170, 1260, 1350, 1440, 1530,
1620, 1710, 1800, 1890, 1980, 2070 or more nucleotides or amino
acids, or with respect to nucleic acids, if the first sequence is
substantially complementary to the complement of the second
sequence.
[0081] v. Subtype or Serotype
[0082] "Subtype" or "serotype": as used herein, interchangeably,
and in reference to influenza virus, means genetic variants of an
influenza virus such that one subtype is recognized by an immune
system apart from a different subtype.
[0083] w. Variant
[0084] "Variant" used herein with respect to a nucleic acid means
(i) a portion or fragment of a referenced nucleotide sequence; (ii)
the complement of a referenced nucleotide sequence or portion
thereof; (iii) a nucleic acid that is substantially identical to a
referenced nucleic acid or the complement thereof; or (iv) a
nucleic acid that hybridizes under stringent conditions to the
referenced nucleic acid, complement thereof, or a sequences
substantially identical thereto.
[0085] "Variant" with respect to a peptide or polypeptide that
differs in amino acid sequence by the insertion, deletion, or
conservative substitution of amino acids, but retain at least one
biological activity. Variant can also mean a protein with an amino
acid sequence that is substantially identical to a referenced
protein with an amino acid sequence that retains at least one
biological activity. A conservative substitution of an amino acid,
i.e., replacing an amino acid with a different amino acid of
similar properties (e.g., hydrophilicity, degree and distribution
of charged regions) is recognized in the art as typically involving
a minor change. These minor changes can be identified, in part, by
considering the hydropathic index of amino acids, as understood in
the art. Kyte et al., J. Mol. Biol. 157:105-132 (1982). The
hydropathic index of an amino acid is based on a consideration of
its hydrophobicity and charge. It is known in the art that amino
acids of similar hydropathic indexes can be substituted and still
retain protein function. In one aspect, amino acids having
hydropathic indexes of .+-.2 are substituted. The hydrophilicity of
amino acids can also be used to reveal substitutions that would
result in proteins retaining biological function. A consideration
of the hydrophilicity of amino acids in the context of a peptide
permits calculation of the greatest local average hydrophilicity of
that peptide, a useful measure that has been reported to correlate
well with antigenicity and immunogenicity. U.S. Pat. No. 4,554,101,
incorporated fully herein by reference. Substitution of amino acids
having similar hydrophilicity values can result in peptides
retaining biological activity, for example immunogenicity, as is
understood in the art. Substitutions can be performed with amino
acids having hydrophilicity values within .+-.2 of each other. Both
the hyrophobicity index and the hydrophilicity value of amino acids
are influenced by the particular side chain of that amino acid.
Consistent with that observation, amino acid substitutions that are
compatible with biological function are understood to depend on the
relative similarity of the amino acids, and particularly the side
chains of those amino acids, as revealed by the hydrophobicity,
hydrophilicity, charge, size, and other properties.
[0086] x. Vector
[0087] "Vector" as used herein means a nucleic acid sequence
containing an origin of replication. A vector can be a vector,
bacteriophage, bacterial artificial chromosome or yeast artificial
chromosome. A vector can be a DNA or RNA vector. A vector can be a
self-replicating extrachromosomal vector, and preferably, is a DNA
plasmid.
2. Influenza Antigen
[0088] Provided herein are antigens capable of eliciting an immune
response in a mammal against one or more influenza serotypes. The
antigen can be capable of eliciting an immune response in a mammal
against one or more influenza serotypes, including against one or
more pandemic strains, such as 2009 H1N1 swine originated
influenza. The antigen can be capable of eliciting an immune
response in a mammal against one or more influenza serotype,
including against one or more strains of swine derived human
influenza. The antigen can comprise epitopes that make them
particularly effective as immunogens against which anti-influenza
immune responses can be induced.
[0089] The antigen can comprise the full length translation product
HA0, subunit HA1, subunit HA2, a variant thereof, a fragment
thereof or a combination thereof. The influenza hemagglutinin
antigen can be a consensus sequence derived from multiple strains
of influenza A serotype H1, a consensus sequence derived from
multiple strains of influenza A serotype H2, a hybrid sequence
containing portions of two different consensus sequences derived
from different sets of multiple strains of influenza A serotype H1
or a consensus sequence derived from multiple strains of influenza
B. The influenza hemagglutinin antigen can be from influenza B. The
antigen can contain at least one antigenic epitope that can be
effective against particular influenza immunogens against which an
immune response can be induced. The antigen may provide an entire
repertoire of immunogenic sites and epitopes present in an intact
influenza virus. The antigen may be a consensus hemagglutinin
antigen sequence that can be derived from hemagglutinin antigen
sequences from a plurality of influenza A virus strains of one
serotype such as a plurality of influenza A virus strains of
serotype H1 or of serotype H2. The antigen may be a hybrid
consensus hemagglutinin antigen sequence that can be derived from
combining two different consensus hemagglutinin antigen sequences
or portions thereof. Each of two different consensus hemagglutinin
antigen sequences may be derived from a different set of a
plurality of influenza A virus strains of one serotype such as a
plurality of influenza A virus strains of serotype H1. The antigen
may be a consensus hemagglutinin antigen sequence that can be
derived from hemagglutinin antigen sequences from a plurality of
influenza B virus strains.
[0090] The consensus hemagglutinin antigen may be a protein
comprising SEQ ID NO: 2 (the consensus H1 amino acid sequence)
wherein amino acids 1-343 correspond to the HA1 subunit of the
precursor HA0 consensus H1 amino acid sequence and amino acids
344-566 correspond to the HA2 subunit of the HA0 consensus H1 amino
acid sequence. The consensus hemagglutinin antigen may be a protein
comprising SEQ ID NO: 7 (the consensus H2 amino acid sequence). The
consensus hemagglutinin antigen may be a synthetic hybrid consensus
H1 sequences comprising portions of two different consensus H1
sequences which are each derived from a different set of sequences
from the other. An example of a consensus HA antigen that is a
synthetic hybrid consensus H1 protein is a protein comprising SEQ
ID NO: 10 (the U2 amino acid sequence). The consensus hemagglutinin
antigen may be a consensus hemagglutinin protein derived from
hemagglutinin sequences from influenza B strains, such as a protein
comprising SEQ ID NO: 14 (the consensus BHA amino acid
sequence).
[0091] The consensus hemagglutinin antigen may further comprise one
or more additional amino acid sequence elements. The consensus
hemagglutinin antigen may further comprise on its N-terminal an IgE
or IgG leader amino acid sequence. The IgE leader amino acid
sequence may be SEQ ID NO: 17. The consensus hemagglutinin antigen
may further comprise an immunogenic tag which is a unique
immunogenic epitope that can be detected by readily available
antibodies. An example of such an immunogenic tag is the 9 amino
acid influenza HA Tag which may be linked on the consensus
hemagglutinin C terminus. The HA Tag amino acid sequence may be SEQ
ID NO:18. In some embodiments, consensus hemagglutinin antigen may
further comprise on its N-terminal an IgE or IgG leader amino acid
sequence and on its C terminal an HA tag.
[0092] The consensus hemagglutinin antigen may be a consensus
hemagglutinin protein that consists of consensus influenza amino
acid sequences or fragments and variants thereof. The consensus
hemagglutinin antigen may be a consensus hemagglutinin protein that
comprises non-influenza protein sequences and influenza protein
sequences or fragments and variants thereof.
[0093] Examples of a consensus H1 protein include those that may
consist of the consensus H1 amino acid sequence (SEQ ID NO:2) or
those that further comprise additional elements such as an IgE
leader sequence, or an HA Tag or both an IgE leader sequence and an
HA Tag. An example of the consensus H1 protein that includes both
an IgE leader sequence and an HA Tag is SEQ ID NO: 4, which
comprises the consensus H1 amino acid coding sequence (SEQ ID NO:2)
linked to the IgE leader amino acid sequence (SEQ ID NO: 17) at its
N terminal and linked to the HA Tag (SEQ ID NO:18) at its C
terminal.
[0094] Examples of consensus H2 proteins include those that may
consist of the consensus H2 amino acid sequence (SEQ ID NO:7) or
those that further comprise an IgE leader sequence, or an HA Tag,
or both an IgE leader sequence and an HA Tag.
[0095] Examples of hybrid consensus H1 proteins include those that
may consist of the consensus U2 amino acid sequence (SEQ ID NO:10)
or those that further comprise an IgE leader sequence, or an HA
Tag, or both an IgE leader sequence and an HA Tag. An example of
the consensus U2 protein is SEQ ID NO:12, which comprises the
consensus U2 amino acid sequence (SEQ ID NO:10) linked to the IgE
leader amino acid sequence (SEQ ID NO: 17) at its N terminal and
linked to the HA Tag (SEQ ID NO:18) at its C terminal.
[0096] Examples of hybrid consensus influenza B hemagglutinin
proteins include those that may consist of the consensus BHA amino
acid sequence (SEQ ID NO:14) or it may comprise an IgE leader
sequence, or a an HA Tag, or both an IgE leader sequence and an HA
Tag. An example of the consensus BHA protein is SEQ ID NO:16 which
comprises the consensus BHA amino acid sequence (SEQ ID NO:14)
linked to the IgE leader amino acid sequence (SEQ ID NO: 17) at its
N terminal and linked to the HA Tag (SEQ ID NO:18) at its C
terminal.
[0097] The consensus hemagglutinin protein can be encoded by a
consensus hemagglutinin nucleic acid, a variant thereof or a
fragment thereof. Unlike the consensus hemagglutinin protein which
may be a consensus sequence derived from a plurality of different
hemagglutinin sequences from different strains and variants, the
consensus hemagglutinin nucleic acid refers to a nucleic acid
sequence that encodes a consensus protein sequence and the coding
sequences used may differ from those used to encode the particular
amino acid sequences in the plurality of different hemagglutinin
sequences from which the consensus hemagglutinin protein sequence
is derived. The consensus nucleic acid sequence may be codon
optimized and/or RNA optimized. The consensus hemagglutinin nucleic
acid sequence may comprise a Kozak's sequence in the 5'
untranslated region. The consensus hemagglutinin nucleic acid
sequence may comprise nucleic acid sequences that encode a leader
sequence. The coding sequence of an N terminal leader sequence is
5' of the hemagglutinin coding sequence. The N-terminal leader can
be facilitate secretion. The N-terminal leader can be an IgE leader
or an IgG leader. The consensus hemagglutinin nucleic acid sequence
can comprise nucleic acid sequences that encode an immunogenic tag.
The immunogenic tag can be on the C terminus of the protein and the
sequence encoding it is 3' of the HA coding sequence. The
immunogenic tag provides a unique epitope for which there are
readily available antibodies so that such antibodies can be used in
assays to detect and confirm expression of the protein. The
immunogenic tag can be an H Tag at the C-terminus of the
protein.
[0098] Consensus hemagglutinin nucleic acid may have a
polynucleotide sequence that encodes a protein that comprises the
amino acid sequence of SEQ ID NO: 2, SEQ ID NO:7, SEQ ID NO:10 or
SEQ ID NO:14. A consensus hemagglutinin nucleic acid that encodes
SEQ ID NO: 2, SEQ ID NO:7, SEQ ID NO:10 or SEQ ID NO:14 may be SEQ
ID NO:1, SEQ ID NO:6, SEQ ID NO:9 or SEQ ID NO:13, respectively.
The consensus hemagglutinin nucleic acid can further comprise a
polynucleotide sequence encoding the IgE leader amino acid
sequence, or a polynucleotide sequence encoding an HA Tag amino
acid sequence, or both. SEQ ID NO: 17 is an IgE leader polypeptide
sequence. SEQ ID NO: 18 is an HA Tag polypeptide sequence. Examples
of hemagglutinin consensus nucleic acids that further comprise
polynucleotide sequences encoding an IgE leader sequence and an HA
Tag include nucleic acid molecules that encode proteins that
comprise the amino acid sequence of SEQ ID NO:4, SEQ ID NO:12 or
SEQ ID NO:16. A consensus hemagglutinin nucleic acid that encodes
SEQ ID NO:4, SEQ ID NO:12 or SEQ ID NO:16 may be SEQ ID NO:3, SEQ
ID NO:11 or SEQ ID NO:15, respectively.
3. Genetic Constructs and Plasmids
[0099] Provided herein are genetic constructs that can comprise a
nucleic acid sequence that encodes the hemagglutinin antigen. The
genetic construct can be present in the cell as a functioning
extrachromosomal molecule comprising the nucleic acid encoding the
hemagglutinin antigen. The genetic construct comprising the nucleic
acid encoding the hemagglutinin antigen can be linear
minichromosome including centromere, telomers or plasmids or
cosmids.
[0100] The genetic construct can also be part of a genome of a
recombinant viral vector, including recombinant adenovirus,
recombinant adenovirus associated virus and recombinant vaccinia.
The genetic construct can be part of the genetic material in
attenuated live microorganisms or recombinant microbial vectors
which live in cells.
[0101] The genetic constructs can comprise regulatory elements for
gene expression of the hemagglutinin nucleic acid. The regulatory
elements can be a promoter, an enhancer an initiation codon, a stop
codon, or a polyadenylation signal.
[0102] Compositions may comprise a first nucleic acid sequence
which encodes the hemagglutinin consensus antigen selected from the
group consisting of one or more of: influenza A consensus
hemagglutinin H1 antigen, influenza A consensus hemagglutinin H2
antigen, influenza A consensus hemagglutinin U2 antigen, and
influenza B consensus hemagglutinin protein BHA, and may further
comprise one or more additional nucleic acid sequence(s) that
encodes one or more protein(s) selected from the group consisting
of: influenza A hemagglutinin proteins H1, H2, H3, H4, H5, H6, H7,
H8, H9, H10, H11, H12, H13, H14, H15, H16, influenza A
neuraminidase N1, N2, N3, N4, N5, N6, N7, N8, N9, influenza B
hemagglutinin (BHA) and influenza B neuraminidase (BNA). The first
and additional nucleic acid sequences may be present on the same
nucleic acid molecule or different nucleic acid molecules. The
first and additional nucleic acid sequences can be under the
control of regulatory elements that function in a human cell. The
additional coding sequence may encode one or more H1, H2, H3, H4,
H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, N1, N2, N3,
N4, N5, N6, N7, N8, N9, BHA and BNA from one or more strains of
influenza, or be a consensus derived from a plurality of strains
having the serotype, or be a hybrid which includes sequences from
two or more consensus sequences.
[0103] The nucleic acid sequences may make up a genetic construct
that can be a vector. The vector can be capable of expressing a
consensus hemagglutinin antigen in the cell of a mammal in a
quantity effective to elicit an immune response in the mammal. The
vector can be recombinant. The vector can comprise heterologous
nucleic acid encoding the consensus hemagglutinin antigen. The
vector can be a plasmid. The vector can be useful for transfecting
cells with nucleic acid encoding a consensus hemagglutinin antigen,
which the transformed host cell is cultured and maintained under
conditions wherein expression of the consensus hemagglutinin
antigen takes place.
[0104] The vector can comprise heterologous nucleic acid encoding a
consensus hemagglutinin antigen and can further comprise an
initiation codon, which can be upstream of the consensus
hemagglutinin coding sequence, and a stop codon, which can be
downstream of the consensus hemagglutinin coding sequence. The
initiation and termination codon can be in frame with the consensus
hemagglutinin coding sequence. The vector can also comprise a
promoter that is operably linked to the consensus hemagglutinin
coding sequence. The promoter operably linked to the consensus
hemagglutinin coding sequence can be a promoter from simian virus
40 (SV40), a mouse mammary tumor virus (MMTV) promoter, a human
immunodeficiency virus (HIV) promoter such as the bovine
immunodeficiency virus (BIV) long terminal repeat (LTR) promoter, a
Moloney virus promoter, an avian leukosis virus (ALV) promoter, a
cytomegalovirus (CMV) promoter such as the CMV immediate early
promoter, Epstein Barr virus (EBV) promoter, or a Rous sarcoma
virus (RSV) promoter. The promoter can also be a promoter from a
human gene such as human actin, human myosin, human hemoglobin,
human muscle creatine, or human metalothionein. The promoter can
also be a tissue specific promoter, such as a muscle or skin
specific promoter, natural or synthetic. Examples of such promoters
are described in US patent application publication no.
US20040175727, the contents of which are incorporated herein in its
entirety.
[0105] The vector can also comprise a polyadenylation signal, which
can be downstream of the HA coding sequence. The polyadenylation
signal can be a SV40 polyadenylation signal, LTR polyadenylation
signal, bovine growth hormone (bGH) polyadenylation signal, human
growth hormone (hGH) polyadenylation signal, or human .beta.-globin
polyadenylation signal. The SV40 polyadenylation signal can be a
polyadenylation signal from a pCEP4 vector (Invitrogen, San Diego,
Calif.).
[0106] The vector can also comprise an enhancer upstream of the
consensus hemagglutinin coding. The enhancer can be necessary for
DNA expression. The enhancer can be human actin, human myosin,
human hemoglobin, human muscle creatine or a viral enhancer such as
one from CMV, HA, RSV or EBV. Polynucleotide function enhances are
described in U.S. Pat. Nos. 5,593,972, 5,962,428, and WO94/016737,
the contents of each are fully incorporated by reference.
[0107] The vector can also comprise a mammalian origin of
replication in order to maintain the vector extrachromosomally and
produce multiple copies of the vector in a cell. The vector can be
pVAX1 (FIG. 1), pCEP4 or pREP4 from Invitrogen (San Diego, Calif.),
which can comprise the Epstein Barr virus origin of replication and
nuclear antigen EBNA-1 coding region, which can produce high copy
episomal replication without integration. The vector can be pVAX1
with changes such as those described in the paragraph referring to
FIG. 1 in the Brief Description of the Figures section above. The
backbone of the vector can be pAV0242. The vector can be a
replication defective adenovirus type 5 (Ad5) vector.
[0108] The vector can also comprise a regulatory sequence, which
can be well suited for gene expression in a mammalian or human cell
into which the vector is administered. The consensus hemagglutinin
coding sequence can comprise a codon, which can allow more
efficient transcription of the coding sequence in the host
cell.
[0109] The vector can be pSE420 (Invitrogen, San Diego, Calif.),
which can be used for protein production in Escherichia coli (E.
coli). The vector can also be pYES2 (Invitrogen, San Diego,
Calif.), which can be used for protein production in Saccharomyces
cerevisiae strains of yeast. The vector can also be of the
MAXBAC.TM. complete baculovirus expression system (Invitrogen, San
Diego, Calif.), which can be used for protein production in insect
cells. The vector can also be pcDNA I or pcDNA3 (Invitrogen, San
Diego, Calif.), which maybe used for protein production in
mammalian cells such as Chinese hamster ovary (CHO) cells. The
vector can be expression vectors or systems to produce protein by
routine techniques and readily available starting materials
including Sambrook et al., Molecular Cloning an Laboratory Manual,
Second Ed., Cold Spring Harbor (1989), which is incorporated fully
by reference.
[0110] The vector can be pGX2009 or pGX2006, which can be used for
expressing the consensus hemagglutinin antigen. The vector pGX2009
(4739 bp, FIG. 2; SEQ ID NO: 5) is a modified pVAX1 plasmid with a
nucleic acid sequence that encodes a consensus H1 protein (amino
acid SEQ ID NO:4 encoded by SEQ ID NO:3) that comprises an IgE
leader sequence (amino acid SEQ ID NO:12 encoded by SEQ ID NO:11)
linked to a consensus H1 amino acid sequence (amino acid SEQ ID
NO:2 encoded by SEQ ID NO:1). The vector pGX2006 (4628 bp; FIG. 3,
SEQ ID NO:8) is a pVAX1 plasmid with a nucleic acid sequence that
encodes a consensus H2 protein (amino acid SEQ ID NO:7 encoded by
SEQ ID NO:6).
[0111] The genetic constructs and components disclosed herein which
include consensus hemagglutinin coding sequences may be used to
express other influenza proteins such as influenza A H1, H2, H3,
H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, N1, N2,
N3, N4, N5, N6, N7, N8, N9, influenza B hemagglutinin or
neuraminidase protein whereby coding sequences for influenza A
proteins H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13,
H14, H15, H16, N1, N2, N3, N4, N5, N6, N7, N8, N9, influenza B
hemagglutinin or neuraminidase protein are included in place of
consensus hemagglutinin coding sequences.
4. Pharmaceutical Compositions
[0112] Provided herein are pharmaceutical compositions according to
the present invention which comprise about 1 nanogram to about 10
mg of DNA. In some embodiments, pharmaceutical compositions
according to the present invention comprise from between: 1) at
least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,
85, 90, 95 or 100 nanograms, or at least 1, 5, 10, 15, 20, 25, 30,
35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110,
115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175,
180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240,
245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305,
310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370,
375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435,
440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500,
605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665,
670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730,
735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795,
800, 805, 810, 815, 820, 825, 830, 835, 840, 845, 850, 855, 860,
865, 870, 875, 880, 885, 890, 895, 900, 905, 910, 915, 920, 925,
930, 935, 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990,
995 or 1000 micrograms, or at least 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5,
5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 mg or more; and 2) up to
and including 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75,
80, 85, 90, 95 or 100 nanograms, or up to and including 1, 5, 10,
15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,
100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160,
165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225,
230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290,
295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355,
360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420,
425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485,
490, 495, 500, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650,
655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715,
720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780,
785, 790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845,
850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910,
915, 920, 925, 930, 935, 940, 945, 950, 955, 960, 965, 970, 975,
980, 985, 990, 995, or 1000 micrograms, or up to and including 1.5,
2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or
10 mg. In some embodiments, pharmaceutical compositions according
to the present invention comprise about 5 nanogram to about 10 mg
of DNA. In some embodiments, pharmaceutical compositions according
to the present invention comprise about 25 nanogram to about 5 mg
of DNA. In some embodiments, the pharmaceutical compositions
contain about 50 nanograms to about 1 mg of DNA. In some
embodiments, the pharmaceutical compositions contain about 0.1 to
about 500 micrograms of DNA. In some embodiments, the
pharmaceutical compositions contain about 1 to about 350 micrograms
of DNA. In some embodiments, the pharmaceutical compositions
contain about 5 to about 250 micrograms of DNA. In some
embodiments, the pharmaceutical compositions contain about 10 to
about 200 micrograms of DNA. In some embodiments, the
pharmaceutical compositions contain about 15 to about 150
micrograms of DNA. In some embodiments, the pharmaceutical
compositions contain about 20 to about 100 micrograms of DNA. In
some embodiments, the pharmaceutical compositions contain about 25
to about 75 micrograms of DNA. In some embodiments, the
pharmaceutical compositions contain about 30 to about 50 micrograms
of DNA. In some embodiments, the pharmaceutical compositions
contain about 35 to about 40 micrograms of DNA. In some
embodiments, the pharmaceutical compositions contain about 100 to
about 200 microgram DNA. In some embodiments, the pharmaceutical
compositions comprise about 10 microgram to about 100 micrograms of
DNA. In some embodiments, the pharmaceutical compositions comprise
about 20 micrograms to about 80 micrograms of DNA. In some
embodiments, the pharmaceutical compositions comprise about 25
micrograms to about 60 micrograms of DNA. In some embodiments, the
pharmaceutical compositions comprise about 30 nanograms to about 50
micrograms of DNA. In some embodiments, the pharmaceutical
compositions comprise about 35 nanograms to about 45 micrograms of
DNA. In some preferred embodiments, the pharmaceutical compositions
contain about 0.1 to about 500 micrograms of DNA. In some preferred
embodiments, the pharmaceutical compositions contain about 1 to
about 350 micrograms of DNA. In some preferred embodiments, the
pharmaceutical compositions contain about 25 to about 250
micrograms of DNA. In some preferred embodiments, the
pharmaceutical compositions contain about 100 to about 200
microgram DNA.
[0113] The pharmaceutical compositions according to the present
invention are formulated according to the mode of administration to
be used. In cases where pharmaceutical compositions are injectable
pharmaceutical compositions, they are sterile, pyrogen free and
particulate free. An isotonic formulation is preferably used.
Generally, additives for isotonicity can include sodium chloride,
dextrose, mannitol, sorbitol and lactose. In some cases, isotonic
solutions such as phosphate buffered saline are preferred.
Stabilizers include gelatin and albumin. In some embodiments, a
vasoconstriction agent is added to the formulation.
[0114] Preferably the pharmaceutical composition is a vaccine, and
more preferably a DNA vaccine.
[0115] Provided herein is a vaccine capable of generating in a
mammal an immune response against one or more influenza serotypes.
The vaccine can comprise the genetic construct as discussed above.
The vaccine can comprise a plurality of the vectors each directed
to one or more Influenza A serotypes such as H1-H16 Influenza B
hemagglutinin or combinations thereof. The vaccine may comprise one
or more nucleic acid sequences that encode one or more consensus
hemagglutinin antigens. When the vaccine comprises more than one
consensus hemagglutinin nucleic acid sequences, all such sequences
may be present on a single nucleic acid molecule or each such
sequences may be present on a different nucleic acid molecule.
Alternatively, vaccines that comprise more than one consensus
hemagglutinin nucleic acid sequences may comprise nucleic acid
molecules with a single consensus hemagglutinin nucleic acid
sequences and nucleic acid molecules with more than one consensus
hemagglutinin nucleic acid sequences. In addition, vaccines
comprising one or more consensus hemagglutinin nucleic acid
sequences may further comprise coding sequences for one or more
proteins selected from the group consisting of H1, H2, H3, H4, H5,
H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, N1, N2, N3, N4,
N5, N6, N7, N8, N9 and influenza B neuraminise.
[0116] In some embodiments, vaccines may comprise proteins. Some
vaccines may comprise one or more consensus hemagglutinin antigens
such as H1, H2, U2 and BHA. The vaccines may comprise one or more
other proteins selected from the group consisting of H1, H2, H3,
H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, N1, N2,
N3, N4, N5, N6, N7, N8, N9 and influenza B neuraminidase. The
vaccines may comprise one or more consensus hemagglutinin antigens
in combination with one or more other proteins selected from the
group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11,
H12, H13, H14, H15, H16, N1, N2, N3, N4, N5, N6, N7, N8, N9,
influenza B hemagglutinin and neuraminidase.
[0117] The vaccine may be a DNA vaccine. The DNA vaccine may
comprise a plurality of the same or different plasmids comprising
one or more of consensus hemagglutinin nucleic acid sequences. The
DNA vaccine may comprise one or more nucleic acid sequences that
encode one or more consensus hemagglutinin antigens. When the DNA
vaccine comprises more than one consensus hemagglutinin nucleic
acid sequences, all such sequences may be present on a single
plasmid, or each such sequences may be present on a different
plasmids, or some plasmids may comprise a single consensus
hemagglutinin nucleic acid sequences while other plasmids have more
than one consensus hemagglutinin nucleic acid sequences. In
addition, DNA vaccines may further comprise one or more consensus
coding sequences for one or more proteins selected from the group
consisting of influenza A H1, H2, H3, H4, H5, H6, H7, H8, H9, H10,
H11, H12, H13, H14, H15, H16, N1, N2, N3, N4, N5, N6, N7, N8, N9,
influenza B hemagglutinin and neuramidase. Such additional coding
sequences may be on the same or different plasmids from each other
and from the plasmids comprising one or more of consensus
hemagglutinin nucleic acid sequences.
[0118] In some embodiments, vaccines may comprise nucleic acid
sequences that encode influenza antigens in combination with
influenza antigens. In some embodiments, the nucleic acid sequences
encode one or more consensus hemagglutinin antigens such as H1, H2,
U2 and BHA. In some embodiments, the nucleic acid sequences encode
one or more one or more other proteins selected from the group
consisting of, influenza A H1, H2, H3, H4, H5, H6, H7, H8, H9, H10,
H11, H12, H13, H14, H15, H16, N1, N2, N3, N4, N5, N6, N7, N8, N9,
influenza B hemagglutinin and neuramidase. In some embodiments, the
vaccines comprise one or more consensus hemagglutinin antigens such
as H1, H2, U2 and BHA. In some embodiments, the vaccines comprise
one or more one or more other proteins selected from the group
consisting of influenza A H1, H2, H3, H4, H5, H6, H7, H8, 1-19,
H10, H11, H12, H13, H14, H15, H16, N1, N2, N3, N4, N5, N6, N7, N8,
N9, influenza B hemagglutinin and neuramidase.
[0119] In some embodiments, vaccines comprise a combination of
three or more consensus hemagglutinin nucleic acid sequences
including those encoding one or more of H1, H2, U2 and BHA. In some
embodiments, vaccines comprise a combination of three or more
hemagglutinin nucleic acid sequences including those encoding
consensus U2, consensus BHA and an H3 hemagglutinin. In some
embodiments, vaccines comprise a combination of three or more
hemagglutinin nucleic acid sequences including those encoding
consensus BHA, an H1 hemagglutinin and an H3 hemagglutinin. In some
embodiments, vaccines comprise one or more nucleic acid sequences
that encode one or more influenza antigens disclosed in U.S. Ser.
No. 12/375,518, which is incorporated herein by reference and/or
U.S. Ser. No. 12/269,824, which is incorporated herein by
reference. In some embodiments, vaccines comprise a nucleic acid
sequence that encodes an H1 hemagglutinin from U.S. Ser. No.
12/375,518 (SEQ ID NO:36 therein) and/or U.S. Ser. No. 12/269,824
(SEQ ID NO:9 therein). In some embodiments, vaccines comprise a
nucleic acid sequence that encodes an H3 hemagglutinin from U.S.
Ser. No. 12/269,824 (SEQ ID NO:11 therein).
[0120] In some embodiments, vaccines comprise a combination of
three or more consensus hemagglutinin proteins including one or
more of H1, H2, U2 and BHA. In some embodiments, vaccines comprise
a combination of three or more hemagglutinin proteins including
consensus U2, consensus BHA and an H3 hemagglutinin. In some
embodiments, vaccines comprise a combination of three or more
hemagglutinin proteins including consensus BRA, an H1 hemagglutinin
and an H3 hemagglutinin. In some embodiments, vaccines comprise one
or more antigens from U.S. Ser. No. 12/375,518 and/or U.S. Ser. No.
12/269,824. In some embodiments, vaccines comprise an H1
hemagglutinin disclosed in U.S. Ser. No. 12/375,518 (SEQ ID NO:37
therein) and/or U.S. Ser. No. 12/269,824 (SEQ ID NO:10 therein). In
some embodiments, vaccines comprise an H3 hemagglutinin disclosed
in U.S. Ser. No. 12/269,824 (SEQ ID NO:12 therein).
[0121] In some embodiments, vaccines comprise a combination of 1)
the consensus hemagglutinin U2 protein and/or a nucleic acid
sequences encoding the consensus hemagglutinin U2 protein, 2) the
consensus hemagglutinin BHA protein and/or a nucleic acid sequences
encoding the consensus hemagglutinin BHA protein, and 3) a
hemagglutinin H3 protein disclosed in U.S. Ser. No. 12/269,824 (SEQ
ID NO:12 therein) and/or a nucleic acid sequences encoding
hemagglutinin H3 protein disclosed in U.S. Ser. No. 12/269,824 (SEQ
ID NO:11 therein).
[0122] In some embodiments, vaccines comprise a combination of 1)
the consensus hemagglutinin BHA protein and/or a nucleic acid
sequences encoding the consensus hemagglutinin BHA protein, 2) a
hemagglutinin H1 protein disclosed in U.S. Ser. No. 12/269,824 (SEQ
ID NO:10 therein) or U.S. Ser. No. 12/375,518 (SEQ ID NO:37
therein) and/or a nucleic acid sequences encoding hemagglutinin H1
protein disclosed in U.S. Ser. No. 12/269,824 (SEQ ID NO:9 therein)
or U.S. Ser. No. 12/375,518 (SEQ ID NO:36 therein), and 3) a
hemagglutinin H3 protein disclosed in U.S. Ser. No. 12/269,824 (SEQ
ID NO:12 therein) and/or a nucleic acid sequences encoding
hemagglutinin H3 protein disclosed in U.S. Ser. No. 12/269,824 (SEQ
ID NO:11 therein).
[0123] DNA vaccines are disclosed in U.S. Pat. Nos. 5,593,972,
5,739,118, 5,817,637, 5,830,876, 5,962,428, 5,981,505, 5,580,859,
5,703,055, and 5,676,594, which are incorporated herein fully by
reference. The DNA vaccine can further comprise elements or
reagents that inhibit it from integrating into the chromosome. The
vaccine can be an RNA of the hemagglutinin antigen. The RNA vaccine
can be introduced into the cell.
[0124] The vaccine can be a recombinant vaccine comprising the
genetic construct or antigen described above. The vaccine can also
comprise one or more consensus hemagglutinin antigen in the form of
one or more protein subunits, one or more killed influenza
particles comprising one or more consensus hemagglutinin antigens,
or one or more attenuated influenza particles comprising one or
more consensus hemagglutinin antigens. The attenuated vaccine can
be attenuated live vaccines, killed vaccines and vaccines that use
recombinant vectors to deliver foreign genes that encode one or
more consensus hemagglutinin antigens, and well as subunit and
glycoprotein vaccines. Examples of attenuated live vaccines, those
using recombinant vectors to deliver foreign antigens, subunit
vaccines and glycoprotein vaccines are described in U.S. Pat. Nos.
4,510,245; 4,797,368; 4,722,848; 4,790,987; 4,920,209; 5,017,487;
5,077,044; 5,110,587; 5,112,749; 5,174,993; 5,223,424; 5,225,336;
5,240,703; 5,242,829; 5,294,441; 5,294,548; 5,310,668; 5,387,744;
5,389,368; 5,424,065; 5,451,499; 5,453,364; 5,462,734; 5,470,734;
5,474,935; 5,482,713; 5,591,439; 5,643,579; 5,650,309; 5,698,202;
5,955,088; 6,034,298; 6,042,836; 6,156,319 and 6,589,529, which are
each incorporated herein by reference.
[0125] The vaccine can comprise vectors and/or proteins directed to
Influenza A serotypes from particular regions in the world, for
example, Asia. The vaccine can also be directed against Influenza A
serotypes of swine origin that now infect humans. The vaccine can
comprise vectors and/or proteins directed to Influenza B from
particular regions in the world. The vaccine can also be directed
against Influenza B that infect humans. The vaccine can comprise
one or more vectors and/or one or more proteins directed to one or
more strains of Influenza A and/or B.
[0126] The vaccine provided may be used to induce immune responses
including therapeutic or prophylactic immune responses. Antibodies
and/or killer T cells may be generated which are directed to the
consensus hemagglutinin antigen, and also broadly across multiple
subtypes of influenza viruses. Such antibodies and cells may be
isolated.
[0127] The vaccine can further comprise a pharmaceutically
acceptable excipient. The pharmaceutically acceptable excipient can
be functional molecules as vehicles, adjuvants, carriers, or
diluents. The pharmaceutically acceptable excipient can be a
transfection facilitating agent, which can include surface active
agents, such as immune-stimulating complexes (ISCOMS), Freunds
incomplete adjuvant, LPS analog including monophosphoryl lipid A,
muramyl peptides, quinone analogs, vesicles such as squalene and
squalene, hyaluronic acid, lipids, liposomes, calcium ions, viral
proteins, polyanions, polycations, or nanoparticles, or other known
transfection facilitating agents.
[0128] The transfection facilitating agent is a polyanion,
polycation, including poly-L-glutamate (LGS), or lipid. The
transfection facilitating agent is poly-L-glutamate, and more
preferably, the poly-L-glutamate is present in the vaccine at a
concentration less than 6 mg/ml. The transfection facilitating
agent can also include surface active agents such as
immune-stimulating complexes (ISCOMS), Freunds incomplete adjuvant,
LPS analog including monophosphoryl lipid A, muramyl peptides,
quinone analogs and vesicles such as squalene and squalene, and
hyaluronic acid can also be used administered in conjunction with
the genetic construct. In some embodiments, the DNA vector vaccines
can also include a transfection facilitating agent such as lipids,
liposomes, including lecithin liposomes or other liposomes known in
the art, as a DNA-liposome mixture (see for example WO9324640),
calcium ions, viral proteins, polyanions, polycations, or
nanoparticles, or other known transfection facilitating agents.
Preferably, the transfection facilitating agent is a polyanion,
polycation, including poly-L-glutamate (LGS), or lipid.
Concentration of the transfection agent in the vaccine is less than
4 mg/ml, less than 2 mg/ml, less than 1 mg/ml, less than 0.750
mg/ml, less than 0.500 mg/ml, less than 0.250 mg/ml, less than
0.100 mg/ml, less than 0.050 mg/ml, or less than 0.010 mg/ml.
[0129] The pharmaceutically acceptable excipient may be an
adjuvant. The adjuvant may be other genes that are expressed in
alternative plasmid or are delivered as proteins in combination
with the plasmid above in the vaccine. The adjuvant may be selected
from the group consisting of: .alpha.-interferon (IFN-.alpha.),
.beta.-interferon (IFN-.beta.), .gamma.-interferon, platelet
derived growth factor (PDGF), TNF.alpha., TNF.beta., GM-CSF,
epidermal growth factor (EGF), cutaneous T cell-attracting
chemokine (CTACK), epithelial thymus-expressed chemokine (TECK),
mucosae-associated epithelial chemokine (MEC), IL-12, IL-15, MHC,
CD80, CD86 including IL-15 having the signal sequence deleted and
optionally including the signal peptide from IgE. The adjuvant may
be IL-12, IL-15, IL-28, CTACK, TECK, platelet derived growth factor
(PDGF), TNF.alpha., TNF.beta., GM-CSF, epidermal growth factor
(EGF), IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-18, or a
combination thereof.
[0130] Other genes which may be useful adjuvants include those
encoding: MCP-1, MIP-1a, MIP-1p, IL-8, RANTES, L-selectin,
P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1,
Mac-1, p150.95, PECAM, ICAM-1, ICAM-2, ICAM-3, CD2, LFA-3, M-CSF,
G-CSF, IL-4, mutant forms of IL-18, CD40, CD40L, vascular growth
factor, fibroblast growth factor, IL-7, nerve growth factor,
vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-1,
p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DR5, KILLER,
TRAIL-R2, TRICK2, DR6, Caspase ICE, Fos, c-jun, Sp-1, Ap-1, Ap-2,
p38, p65Rel, MyD88, IRAK, TRAF6, IkB, Inactive NIK, SAP K, SAP-1,
INK, interferon response genes, NFkB, Bax, TRAIL, TRAILrec,
TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, O.times.40,
O.times.40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E,
NKG2F, TAP1, TAP2 and functional fragments thereof.
[0131] The vaccine can further comprise a genetic vaccine
facilitator agent as described in U.S. Ser. No. 021,579 filed Apr.
1, 1994, which is fully incorporated by reference.
5. Methods of Delivery
[0132] Provided herein is a method for delivering the
pharmaceutical formulations, preferably vaccines, for providing
genetic constructs and proteins of the hemagglutinin antigen which
comprise epitopes that make them particular effective immunogens
against which an immune response to influenza viral infections can
be induced. The method of delivering the vaccine, or vaccination,
can be provided to induce a therapeutic and/or prophylactic immune
response. The vaccination process can generate in the mammal an
immune response against a plurality of influenza subtypes,
including a H1N1 serotype, such as the 2009 swine originated H1N1,
or other seasonal and/or pandemic varieties. The vaccine can be
delivered to an individual to modulate the activity of the mammal's
immune system and enhance the immune response. The delivery of the
vaccine can be the transfection of the HA antigen as a nucleic acid
molecule that is expressed in the cell and delivered to the surface
of the cell upon which the immune system recognized and induces a
cellular, humoral, or cellular and humoral response. The delivery
of the vaccine can be use to induce or elicit and immune response
in mammals against a plurality of influenza viruses by
administering to the mammals the vaccine as discussed herein.
[0133] Upon delivery of the vaccine to the mammal, and thereupon
the vector into the cells of the mammal, the transfected cells will
express and secrete the corresponding influenza protein, including
at least one of the consensus antigens, and preferably H1, H2, U2,
and BHA. These secreted proteins, or synthetic antigens, will be
recognized as foreign by the immune system, which will mount an
immune response that can include: antibodies made against the
antigens, and T-cell response specifically against the antigen. In
some examples, a mammal vaccinated with the vaccines discussed
herein will have a primed immune system and when challenged with an
influenza viral strain, the primed immune system will allow for
rapid clearing of subsequent influenza viruses, whether through the
humoral, cellular, or both. The vaccine can be delivered to an
individual to modulate the activity of the individual's immune
system thereby enhancing the immune response.
[0134] The vaccine can be delivered in the form of a DNA vaccine
and methods of delivering a DNA vaccines are described in U.S. Pat.
Nos. 4,945,050 and 5,036,006, which are both incorporated fully by
reference.
[0135] The vaccine can be administered to a mammal to elicit an
immune response in a mammal. The mammal can be human, non-human
primate, cow, pig, sheep, goat, antelope, bison, water buffalo,
bovids, deer, hedgehogs, elephants, llama, alpaca, mice, rats, or
chicken, and preferably human, cow, pig, or chicken.
[0136] a. Combination Treatments
[0137] The pharmaceutical compositions, preferably vaccines, can be
administered in combination with one or more other influenza
proteins or genes encoding influenza A H1, H2, H3, H4, H5, H6, H7,
H8, H9, H10, H11, H12, H13, H14, H15, H16, N1, N2, N3, N4, N5, N6,
N7, N8, N9, influenza B hemagglutinin and neuramidase. The vaccine
can be administered in combination with proteins or genes encoding
adjuvants, which can include: .alpha.-interferon (IFN-.alpha.),
.beta.-interferon (IFN-.beta.), .gamma.-interferon, IL-12, IL-15,
IL-28, CTACK, TECK, platelet derived growth factor (PDGF),
TNF.alpha., TNF.beta., GM-CSF, epidermal growth factor (EGF), IL-1,
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-18, MCP-1, MIP-1a, MIP-1p,
IL-8, RANTES, L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1,
MadCAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-1, ICAM-2,
ICAM-3, CD2, LFA-3, M-CSF, G-CSF, IL-4, mutant forms of IL-18,
CD40, CD40L, vascular growth factor, fibroblast growth factor,
IL-7, nerve growth factor, vascular endothelial growth factor, Fas,
TNF receptor, Flt, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD,
NGRF, DR4, DR5, KILLER, TRAIL-R2, TRICK2, DR6, Caspase ICE, Fos,
c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, IkB,
Inactive NIK, SAP K, SAP-1, JNK, interferon response genes, NFkB,
Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK
LIGAND, O.times.40, O.times.40 LIGAND, NKG2D, MICA, MICB, NKG2A,
NKG2B, NKG2C, NKG2E, NKG2F, TAP1, or TAP2, or functional fragments
thereof.
[0138] b. Routes of Administration
[0139] The vaccine can be administered by different routes
including orally, parenterally, sublingually, transdermally,
rectally, transmucosally, topically, via inhalation, via buccal
administration, intrapleurally, intravenous, intraarterial,
intraperitoneal, subcutaneous, intramuscular, intranasal
intrathecal, and intraarticular or combinations thereof. For
veterinary use, the composition can be administered as a suitably
acceptable formulation in accordance with normal veterinary
practice. The veterinarian can readily determine the dosing regimen
and route of administration that is most appropriate for a
particular animal. The vaccine can be administered by traditional
syringes, needleless injection devices, "microprojectile
bombardment gone guns", or other physical methods such as
electroporation ("EP"), "hydrodynamic method", or ultrasound.
[0140] The vector of the vaccine can be delivered to the mammal by
several well known technologies including DNA injection (also
referred to as DNA vaccination) with and without in vivo
electroporation, liposome mediated, nanoparticle facilitated,
recombinant vectors such as recombinant adenovirus, recombinant
adenovirus associated virus and recombinant vaccinia. The HA
antigen can be delivered via DNA injection and along with in vivo
electroporation.
[0141] c. Electroporation
[0142] Administration of the vaccine via electroporation of the
plasmids of the vaccine may be accomplished using electroporation
devices that can be configured to deliver to a desired tissue of a
mammal a pulse of energy effective to cause reversible pores to
form in cell membranes, and preferable the pulse of energy is a
constant current similar to a preset current input by a user. The
electroporation device may comprise an electroporation component
and an electrode assembly or handle assembly. The electroporation
component may include and incorporate one or more of the various
elements of the electroporation devices, including: controller,
current waveform generator, impedance tester, waveform logger,
input element, status reporting element, communication port, memory
component, power source, and power switch. The electroporation may
be accomplished using an in vivo electroporation device, for
example CELLECTRA.RTM. EP system (VGX Pharmaceuticals, Blue Bell,
Pa.) or Elgen electroporator (Genetronics, San Diego, Calif.) to
facilitate transfection of cells by the plasmid.
[0143] The electroporation component may function as one element of
the electroporation devices, and the other elements are separate
elements (or components) in communication with the electroporation
component. The electroporation component may function as more than
one element of the electroporation devices, which may be in
communication with still other elements of the electroporation
devices separate from the electroporation component. The elements
of the electroporation devices existing as parts of one
electromechanical or mechanical device may not limited as the
elements can function as one device or as separate elements in
communication with one another. The electroporation component may
be capable of delivering the pulse of energy that produces the
constant current in the desired tissue, and includes a feedback
mechanism. The electrode assembly may include an electrode array
having a plurality of electrodes in a spatial arrangement, wherein
the electrode assembly receives the pulse of energy from the
electroporation component and delivers same to the desired tissue
through the electrodes. At least one of the plurality of electrodes
is neutral during delivery of the pulse of energy and measures
impedance in the desired tissue and communicates the impedance to
the electroporation component. The feedback mechanism may receive
the measured impedance and can adjust the pulse of energy delivered
by the electroporation component to maintain the constant
current.
[0144] A plurality of electrodes may deliver the pulse of energy in
a decentralized pattern. The plurality of electrodes may deliver
the pulse of energy in the decentralized pattern through the
control of the electrodes under a programmed sequence, and the
programmed sequence is input by a user to the electroporation
component. The programmed sequence may comprise a plurality of
pulses delivered in sequence, wherein each pulse of the plurality
of pulses is delivered by at least two active electrodes with one
neutral electrode that measures impedance, and wherein a subsequent
pulse of the plurality of pulses is delivered by a different one of
at least two active electrodes with one neutral electrode that
measures impedance.
[0145] The feedback mechanism may be performed by either hardware
or software. The feedback mechanism may be performed by an analog
closed-loop circuit. The feedback occurs every 50 .mu.s, 20 .mu.s,
10 .mu.s or 1 .mu.s, but is preferably a real-time feedback or
instantaneous (i.e., substantially instantaneous as determined by
available techniques for determining response time). The neutral
electrode may measure the impedance in the desired tissue and
communicates the impedance to the feedback mechanism, and the
feedback mechanism responds to the impedance and adjusts the pulse
of energy to maintain the constant current at a value similar to
the preset current. The feedback mechanism may maintain the
constant current continuously and instantaneously during the
delivery of the pulse of energy.
[0146] Examples of electroporation devices and electroporation
methods that may facilitate delivery of the DNA vaccines of the
present invention, include those described in U.S. Pat. No.
7,245,963 by Draghia-Akli, et al., U.S. Patent Pub. 2005/0052630
submitted by Smith, et al., the contents of which are hereby
incorporated by reference in their entirety. Other electroporation
devices and electroporation methods that may be used for
facilitating delivery of the DNA vaccines include those provided in
co-pending and co-owned U.S. patent application Ser. No.
11/874,072, filed Oct. 17, 2007, which claims the benefit under 35
USC 119(e) to U.S. Provisional Application Ser. Nos. 60/852,149,
filed Oct. 17, 2006, and 60/978,982, filed Oct. 10, 2007, all of
which are hereby incorporated in their entirety.
[0147] U.S. Pat. No. 7,245,963 by Draghia-Akli, et al. describes
modular electrode systems and their use for facilitating the
introduction of a biomolecule into cells of a selected tissue in a
body or plant. The modular electrode systems may comprise a
plurality of needle electrodes; a hypodermic needle; an electrical
connector that provides a conductive link from a programmable
constant-current pulse controller to the plurality of needle
electrodes; and a power source. An operator can grasp the plurality
of needle electrodes that are mounted on a support structure and
firmly insert them into the selected tissue in a body or plant. The
biomolecules are then delivered via the hypodermic needle into the
selected tissue. The programmable constant-current pulse controller
is activated and constant-current electrical pulse is applied to
the plurality of needle electrodes. The applied constant-current
electrical pulse facilitates the introduction of the biomolecule
into the cell between the plurality of electrodes. The entire
content of U.S. Pat. No. 7,245,963 is hereby incorporated by
reference.
[0148] U.S. Patent Pub. 2005/0052630 submitted by Smith, et al.
describes an electroporation device which may be used to
effectively facilitate the introduction of a biomolecule into cells
of a selected tissue in a body or plant. The electroporation device
comprises an electro-kinetic device ("EKD device") whose operation
is specified by software or firmware. The EKD device produces a
series of programmable constant-current pulse patterns between
electrodes in an array based on user control and input of the pulse
parameters, and allows the storage and acquisition of current
waveform data. The electroporation device also comprises a
replaceable electrode disk having an array of needle electrodes, a
central injection channel for an injection needle, and a removable
guide disk. The entire content of U.S. Patent Pub. 2005/0052630 is
hereby incorporated by reference.
[0149] The electrode arrays and methods described in U.S. Pat. No.
7,245,963 and U.S. Patent Pub. 2005/0052630 may be adapted for deep
penetration into not only tissues such as muscle, but also other
tissues or organs. Because of the configuration of the electrode
array, the injection needle (to deliver the biomolecule of choice)
is also inserted completely into the target organ, and the
injection is administered perpendicular to the target issue, in the
area that is pre-delineated by the electrodes The electrodes
described in U.S. Pat. No. 7,245,963 and U.S. Patent Pub.
2005/005263 are preferably 20 mm long and 21 gauge.
[0150] Additionally, contemplated in some embodiments that
incorporate electroporation devices and uses thereof, there are
electroporation devices that are those described in the following
patents: U.S. Pat. No. 5,273,525 issued Dec. 28, 1993, U.S. Pat.
Nos. 6,110,161 issued Aug. 29, 2000, 6,261,281 issued Jul. 17,
2001, and 6,958,060 issued Oct. 25, 2005, and U.S. Pat. No.
6,939,862 issued Sep. 6, 2005. Furthermore, patents covering
subject matter provided in U.S. Pat. No. 6,697,669 issued Feb. 24,
2004, which concerns delivery of DNA using any of a variety of
devices, and U.S. Pat. No. 7,328,064 issued Feb. 5, 2008, drawn to
method of injecting DNA are contemplated herein. The above-patents
are incorporated by reference in their entirety.
[0151] d. Method of Preparing Vaccine
[0152] Provided herein is methods for preparing the DNA plasmids
that comprise the DNA vaccines discussed herein. The DNA plasmids,
after the final subcloning step into the mammalian expression
plasmid, can be used to inoculate a cell culture in a large scale
fermentation tank, using known methods in the art.
[0153] The DNA plasmids for use with the EP devices of the present
invention can be formulated or manufactured using a combination of
known devices and techniques, but preferably they are manufactured
using an optimized plasmid manufacturing technique that is
described in a licensed, co-pending U.S. provisional application
U.S. Ser. No. 60/939,792, which was filed on May 23, 2007. In some
examples, the DNA plasmids used in these studies can be formulated
at concentrations greater than or equal to 10 mg/mL. The
manufacturing techniques also include or incorporate various
devices and protocols that are commonly known to those of ordinary
skill in the art, in addition to those described in U.S. Ser. No.
60/939,792, including those described in a licensed patent, U.S.
Pat. No. 7,238,522, which issued on Jul. 3, 2007. The
above-referenced application and patent, U.S. Ser. No. 60/939,792
and U.S. Pat. No. 7,238,522, respectively, are hereby incorporated
in their entirety.
EXAMPLES
[0154] The present invention is further illustrated in the
following Examples. It should be understood that these Examples,
while indicating preferred embodiments of the invention, are given
by way of illustration only. From the above discussion and these
Examples, one skilled in the art can ascertain the essential
characteristics of this invention, and without departing from the
spirit and scope thereof, can make various changes and
modifications of the invention to adapt it to various usages and
conditions. Thus, various modifications of the invention in
addition to those shown and described herein will be apparent to
those skilled in the art from the foregoing description. Such
modifications are also intended to fall within the scope of the
appended claims.
Example 1
[0155] pGX2009 (pH1HA09)--Plasmid Encoding 2009 H1N1 Influenza
(Swine Flu) Hemagglutinin Antigen
[0156] The backbone of pGX2009 (H1HA09) is the modified expression
vector pVAX1 (Invitrogen, Carlsbad, Calif.) under the control of
the cytomegalovirus immediate-early (CMV) promoter. The original
pVAX1 was purchased from Invitrogen (Catalog number V260-20) and
maintained at -20.degree. C. As noted above, sequence analysis
revealed differences between the sequence of pVAX1 used as the
backbone of pGX2009 and the pVAX1 sequence available from
Invitrogen. The differences are set forth above.
[0157] Plasmid pGX2009, also referred to as pH1HA09, comprises a
nucleic acid sequence that encodes a consensus 2009 H1N1 influenza
(swine flu) hemagglutinin molecule. The 79 primary sequences used
to generate the consensus sequence were selected from The Influenza
Sequence Database.
[0158] The accession numbers for nucleotide sequences encoding the
amino acid sequence for the various influenza A hemagglutinin H1
proteins as well as the amino acid sequences encoded by the
nucleotide sequences are in the GenBank database corresponding to
the following accession numbers. The accession numbers not in
parentheses disclose nucleotide sequences and additional list amino
acid sequences encoded by them. The accession numbers in
parentheses are for entries of the corresponding amino acid
sequence in GenBank's protein database.
[0159] The accession numbers are as follows: GQ323579.1
(ACS72657.1), GQ323564.1 (ACS72654.1), GQ323551.1 (ACS72652.1),
GQ323530.1 (ACS72651.1), GQ323520.1 (ACS72650.1), GQ323495.1
(ACS72648.1), GQ323489.1 (ACS72647.1), GQ323486.1 (ACS72646.1),
GQ323483.1 (ACS72645.1), GQ323455.1 (ACS72641.1), GQ323451.1
(ACS72640.1), GQ323443.1 (ACS72638.1), GQ293077.1 (ACS68822.1),
GQ288372.1 (ACS54301.1), GQ287625.1 (ACS54262.1), GQ287627.1
(ACS54263.1), GQ287623.1 (ACS54261.1), GQ287621.1 (ACS54260.1),
GQ286175.1 (ACS54258.1), GQ283488.1 (ACS50088.1), GQ280797.1
(ACS45035.1), GQ280624.1 (ACS45017.1), GQ280121.1 (ACS45189.1),
GQ261277.1 (ACS34968.1), GQ253498.1 (ACS27787.1), GQ323470.1
(ACS72643.1), GQ253492.1 (ACS27780.1), R1981613.1 (ACQ55359.1),
FJ971076.1 (ACP52565.1), FJ969540.1 (ACP44189.1), FJ969511.1
(ACP44150.1), FJ969509.1 (ACP44147.1), GQ255900.1 (ACS27774.1),
GQ255901.1 (ACS27775.1), FJ966974.1 (ACP41953.1), GQ261275.1
(ACS34967.1), FJ966960.1 (ACP41935.1), FJ966952.1 (ACP41926.1),
FJ966082.1 (ACP41105.1), GQ255897.1 (ACS27770.1), CY041645.1
(ACS27249.1), CY041637.1 (ACS27239.1), CY041629 (ACS27229.1),
GQ323446.1 (ACS72639.1), CY041597.1 (ACS27189.1), CY041581.1
(ACS14726.1), CY040653.1 (ACS14666.1), CY041573.1 (ACS14716.1),
CY041565.1 (ACS14706.1), CY041541.1 (ACS14676.1), GQ258462.1
(ACS34667.1), CY041557.1 (ACS14696.1), CY041549.1 (ACS14686.1),
GQ283484.1 (ACS50084.1), GQ283493.1 (ACS50095.1), GQ303340.1
(ACS71656.1), GQ287619.1 (ACS54259.1), GQ267839.1 (ACS36632.1),
GQ268003.1 (ACS36645.1), CY041621.1 (ACS27219.1), CY041613.1
(ACS27209.1), CY041605.1 (ACS27199.1), FJ966959.1 (ACP41934.1),
FJ966982.1 (ACP41963.1), CY039527.2 (ACQ45338.1), FJ981612.1
(ACQ55358.1), FJ981615.1 (ACQ55361.1), FJ982430.1 (ACQ59195.1),
FJ998208.1 (ACQ73386.1), GQ259909.1 (ACS34705.1), GQ261272.1
(ACS34966.1), GQ287621.1 (ACS54260.1), GQ290059.1 (ACS66821.1),
GQ323464.1 (ACS72642.1), GQ323473.1 (ACS72644.1), GQ323509.1
(ACS72649.1), GQ323560.1 (ACS72653.1), GQ323574.1 (ACS72655.1), and
GQ323576.1 (ACS72656.1). The amino acid sequences were downloaded
from the NCBI Sequence Database, and an alignment and consensus
sequence generated using Clustal X. A highly efficient leader
sequence, the IgE leader, was fused in frame upstream of the start
codon to facilitate the expression. In order to have a higher level
of expression, the codon usage of this fusion gene was adapted to
the codon bias of Homo Sapiens genes. In addition, RNA optimization
was also performed: regions of very high (>80%) or very low
(<30%) GC content and the cis-acting sequence motifs such as
internal TATA boxes, chi-sites and ribosomal entry sites were
avoided. The entire sequence was synthetically produced at Geneart
(Regensburg, Germany). The synthetic engineered H1HA09 gene was
1818 bp in length (SEQ ID NO:1) and was cloned into pVAX1 at BamHI
and XhoI sites by Geneart (FIG. 2).
Example 2
[0160] Challenge of Influenza pGX2009 immunized Ferrets with
A/Mexico/InDRE4487/2009
[0161] Challenge experiments were carried out using ferrets, a
preferred model for influenza. The ferrets were immunized using
plasmid pGX2009.
[0162] Animals: 4 groups.times.5 animals/group, plus one control
group with 4 animals=24 ferrets total (male)
[0163] Duration: 18 weeks (including challenge)
[0164] Dose: 0.2 mg plasmid
[0165] Protocol Summary Ferrets were allocated randomly into DNA
vaccine groups. Animals were immunized at Study Day 0, Day 28, and
Day 56. Animals were anesthetized with ketamine/midazolam cocktail,
isoflurane or equivalent according to approved anesthesia protocols
and vaccinated IM with influenza DNA vaccine combinations. Groups 1
and 2 were immediately electroporated using CELLECTRA.RTM. adaptive
constant current electroporation (EP) device at 0.5 Amp, 52
millisecond pulses, 0.2 sec between pulses, 4 sec firing delay, 3
total pulses. Control animals were naive controls (no plasmid, no
EP). Ferrets were allowed to recover from anesthesia in their cages
and were closely monitored for 24 hours to ensure full
recovery.
[0166] Food and water was available ad libitum for the length of
the study. On Day 84, animals were challenged by intranasal
infection with 1 ml of MX10 (A/Mexico/InDRE4487/2009; 5.times.105
PFU/ml). Animals were monitored daily for clinical signs (weight,
temperature, etc.), using an established and approved scoring
sheet. On 1, 3, 6, 9 and 15 dpi nasal washes and rectal swabs were
collected. Lungs were collected at day 15. Samples were stored in
RNAlater for virus load by real-time PCR, medium for infectious
virus (TCDI50) and formalin for histology when appropriated.
[0167] FIG. 4 shows a Hemagglutination Inhibition assay performed
with sera from immunized ferrets (3 immunizations). A titer of
>1:40 is considered "protective". A dotted line indicates the
1:40 mark. All animals were above the 1:40 mark after 3
immunizations. FIG. 5 shows results of a challenge of immunized and
unimmunized ferrets with a novel H1N1 strain MX10
(A/Mexico/InDRE4487/2009). All immunized ferrets survived, while
75% of the naive ferrets died within the 15 day period.
Sequence CWU 1
1
1811695DNAArtificial SequenceInfluenza H1 DNA sequence 1atgaaggcta
tcctcgtcgt gctgctgtac accttcgcca ccgccaacgc cgataccctg 60tgcatcggct
accacgccaa caacagcacc gacaccgtgg ataccgtgct ggaaaagaac
120gtgaccgtga cccacagcgt gaacctgctg gaagataagc acaacggcaa
gctgtgcaag 180ctgagaggcg tggcccctct gcacctgggc aagtgcaata
tcgccggctg gattctgggc 240aaccccgagt gcgagagcct gtctaccgct
agctcctggt cctacatcgt ggagacaagc 300agcagcgaca acggcacctg
ttaccccggc gacttcatcg actacgagga actgcgggag 360cagctgagca
gcgtgtccag cttcgagcgg ttcgagatct tccccaagac cagctcctgg
420cccaaccacg acagcaacaa gggcgtgacc gccgcctgtc ctcacgctgg
cgccaagagc 480ttctacaaga acctgatctg gctggtcaag aagggcaaca
gctaccccaa gctgagcaag 540agctacatca acgacaaggg caaagaggtc
ctcgtcctct ggggcatcca ccaccctagc 600accagcgccg accagcagag
cctgtaccag aacgccgacg cctacgtgtt cgtgggctca 660tctcggtaca
gcaagaagtt caagcccgag atcgccatca gacccaaagt gcgggaccag
720gaaggccgga tgaactacta ctggaccctg gtggagcccg gcgacaagat
caccttcgag 780gccaccggca atctggtggt gcccagatac gccttcgcca
tggaaagaaa cgccggcagc 840ggcatcatca tcagcgacac ccccgtgcac
gactgcaaca ccacctgtca gacccccaag 900ggcgccatca acaccagcct
gcccttccag aacatccacc ccatcaccat cggcaagtgc 960cctaagtacg
tgaagtccac taagctcaga ctggccaccg gcctgagaaa cgtgcccagc
1020atccagagca gaggcctgtt tggcgccatt gccggcttta tcgagggcgg
ctggaccgga 1080atggtggacg ggtggtacgg ctaccaccac cagaatgagc
agggcagcgg ctacgccgcc 1140gacctgaagt ccacacagaa cgccatcgac
gagatcacca acaaagtgaa cagcgtgatc 1200gagaagatga acacccagtt
caccgccgtg ggcaaagagt tcaaccacct ggaaaagcgg 1260atcgagaacc
tgaacaagaa ggtggacgac ggcttcctgg acatctggac ctacaacgcc
1320gagctgctgg tgctgctgga aaacgagcgg accctggact accacgactc
caacgtgaag 1380aatctgtacg agaaagtgcg gagccagctg aagaacaacg
ccaaagagat cggcaacggc 1440tgcttcgagt tctaccacaa gtgcgacaac
acctgtatgg aaagcgtgaa gaacggcacc 1500tacgactacc ccaagtacag
cgaggaagcc aagctgaacc gggaagagat cgacggcgtg 1560aagctggaaa
gcacccggat ctaccagatc ctggccatct actctactgt ggccagctca
1620ctggtgctgg tggtgtccct gggcgccatc tccttttgga tgtgctccaa
cggcagcctg 1680cagtgccgga tctgc 16952566PRTArtificial
SequenceInfluenza Protein H1 Sequence 2Met Lys Ala Ile Leu Val Val
Leu Leu Tyr Thr Phe Ala Thr Ala Asn1 5 10 15Ala Asp Thr Leu Cys Ile
Gly Tyr His Ala Asn Asn Ser Thr Asp Thr 20 25 30Val Asp Thr Val Leu
Glu Lys Asn Val Thr Val Thr His Ser Val Asn 35 40 45Leu Leu Glu Asp
Lys His Asn Gly Lys Leu Cys Lys Leu Arg Gly Val 50 55 60Ala Pro Leu
His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile Leu Gly65 70 75 80Asn
Pro Glu Cys Glu Ser Leu Ser Thr Ala Ser Ser Trp Ser Tyr Ile 85 90
95Val Glu Thr Ser Ser Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe
100 105 110Ile Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser
Ser Phe 115 120 125Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp
Pro Asn His Asp 130 135 140Ser Asn Lys Gly Val Thr Ala Ala Cys Pro
His Ala Gly Ala Lys Ser145 150 155 160Phe Tyr Lys Asn Leu Ile Trp
Leu Val Lys Lys Gly Asn Ser Tyr Pro 165 170 175Lys Leu Ser Lys Ser
Tyr Ile Asn Asp Lys Gly Lys Glu Val Leu Val 180 185 190Leu Trp Gly
Ile His His Pro Ser Thr Ser Ala Asp Gln Gln Ser Leu 195 200 205Tyr
Gln Asn Ala Asp Ala Tyr Val Phe Val Gly Ser Ser Arg Tyr Ser 210 215
220Lys Lys Phe Lys Pro Glu Ile Ala Ile Arg Pro Lys Val Arg Asp
Gln225 230 235 240Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu
Pro Gly Asp Lys 245 250 255Ile Thr Phe Glu Ala Thr Gly Asn Leu Val
Val Pro Arg Tyr Ala Phe 260 265 270Ala Met Glu Arg Asn Ala Gly Ser
Gly Ile Ile Ile Ser Asp Thr Pro 275 280 285Val His Asp Cys Asn Thr
Thr Cys Gln Thr Pro Lys Gly Ala Ile Asn 290 295 300Thr Ser Leu Pro
Phe Gln Asn Ile His Pro Ile Thr Ile Gly Lys Cys305 310 315 320Pro
Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg 325 330
335Asn Val Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly
340 345 350Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp Tyr
Gly Tyr 355 360 365His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala
Asp Leu Lys Ser 370 375 380Thr Gln Asn Ala Ile Asp Glu Ile Thr Asn
Lys Val Asn Ser Val Ile385 390 395 400Glu Lys Met Asn Thr Gln Phe
Thr Ala Val Gly Lys Glu Phe Asn His 405 410 415Leu Glu Lys Arg Ile
Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe 420 425 430Leu Asp Ile
Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn 435 440 445Glu
Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys Asn Leu Tyr Glu 450 455
460Lys Val Arg Ser Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn
Gly465 470 475 480Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys
Met Glu Ser Val 485 490 495Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr
Ser Glu Glu Ala Lys Leu 500 505 510Asn Arg Glu Glu Ile Asp Gly Val
Lys Leu Glu Ser Thr Arg Ile Tyr 515 520 525Gln Ile Leu Ala Ile Tyr
Ser Thr Val Ala Ser Ser Leu Val Leu Val 530 535 540Val Ser Leu Gly
Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu545 550 555 560Gln
Cys Arg Ile Cys Ile 56531818DNAArtificial SequenceIgE-H1-HAT
Antigen DNA Sequence 3ttaattaagg atccgccacc atggactgga cctggattct
gttcctggtg gctgctgcca 60ctagagtgca cagcatgaag gctatcctcg tcgtgctgct
gtacaccttc gccaccgcca 120acgccgatac cctgtgcatc ggctaccacg
ccaacaacag caccgacacc gtggataccg 180tgctggaaaa gaacgtgacc
gtgacccaca gcgtgaacct gctggaagat aagcacaacg 240gcaagctgtg
caagctgaga ggcgtggccc ctctgcacct gggcaagtgc aatatcgccg
300gctggattct gggcaacccc gagtgcgaga gcctgtctac cgctagctcc
tggtcctaca 360tcgtggagac aagcagcagc gacaacggca cctgttaccc
cggcgacttc atcgactacg 420aggaactgcg ggagcagctg agcagcgtgt
ccagcttcga gcggttcgag atcttcccca 480agaccagctc ctggcccaac
cacgacagca acaagggcgt gaccgccgcc tgtcctcacg 540ctggcgccaa
gagcttctac aagaacctga tctggctggt caagaagggc aacagctacc
600ccaagctgag caagagctac atcaacgaca agggcaaaga ggtcctcgtc
ctctggggca 660tccaccaccc tagcaccagc gccgaccagc agagcctgta
ccagaacgcc gacgcctacg 720tgttcgtggg ctcatctcgg tacagcaaga
agttcaagcc cgagatcgcc atcagaccca 780aagtgcggga ccaggaaggc
cggatgaact actactggac cctggtggag cccggcgaca 840agatcacctt
cgaggccacc ggcaatctgg tggtgcccag atacgccttc gccatggaaa
900gaaacgccgg cagcggcatc atcatcagcg acacccccgt gcacgactgc
aacaccacct 960gtcagacccc caagggcgcc atcaacacca gcctgccctt
ccagaacatc caccccatca 1020ccatcggcaa gtgccctaag tacgtgaagt
ccactaagct cagactggcc accggcctga 1080gaaacgtgcc cagcatccag
agcagaggcc tgtttggcgc cattgccggc tttatcgagg 1140gcggctggac
cggaatggtg gacgggtggt acggctacca ccaccagaat gagcagggca
1200gcggctacgc cgccgacctg aagtccacac agaacgccat cgacgagatc
accaacaaag 1260tgaacagcgt gatcgagaag atgaacaccc agttcaccgc
cgtgggcaaa gagttcaacc 1320acctggaaaa gcggatcgag aacctgaaca
agaaggtgga cgacggcttc ctggacatct 1380ggacctacaa cgccgagctg
ctggtgctgc tggaaaacga gcggaccctg gactaccacg 1440actccaacgt
gaagaatctg tacgagaaag tgcggagcca gctgaagaac aacgccaaag
1500agatcggcaa cggctgcttc gagttctacc acaagtgcga caacacctgt
atggaaagcg 1560tgaagaacgg cacctacgac taccccaagt acagcgagga
agccaagctg aaccgggaag 1620agatcgacgg cgtgaagctg gaaagcaccc
ggatctacca gatcctggcc atctactcta 1680ctgtggccag ctcactggtg
ctggtggtgt ccctgggcgc catctccttt tggatgtgct 1740ccaacggcag
cctgcagtgc cggatctgca tctaccccta cgacgtgccc gactacgcct
1800gatgactcga ggcgcgcc 18184593PRTArtificial
SequenceIgE-H1-HATanitgen amino acid seqeunce 4Met Asp Trp Thr Trp
Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val1 5 10 15His Ser Met Lys
Ala Ile Leu Val Val Leu Leu Tyr Thr Phe Ala Thr 20 25 30Ala Asn Ala
Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr 35 40 45Asp Thr
Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser 50 55 60Val
Asn Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Arg65 70 75
80Gly Val Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile
85 90 95Leu Gly Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Ser Ser Trp
Ser 100 105 110Tyr Ile Val Glu Thr Ser Ser Ser Asp Asn Gly Thr Cys
Tyr Pro Gly 115 120 125Asp Phe Ile Asp Tyr Glu Glu Leu Arg Glu Gln
Leu Ser Ser Val Ser 130 135 140Ser Phe Glu Arg Phe Glu Ile Phe Pro
Lys Thr Ser Ser Trp Pro Asn145 150 155 160His Asp Ser Asn Lys Gly
Val Thr Ala Ala Cys Pro His Ala Gly Ala 165 170 175Lys Ser Phe Tyr
Lys Asn Leu Ile Trp Leu Val Lys Lys Gly Asn Ser 180 185 190Tyr Pro
Lys Leu Ser Lys Ser Tyr Ile Asn Asp Lys Gly Lys Glu Val 195 200
205Leu Val Leu Trp Gly Ile His His Pro Ser Thr Ser Ala Asp Gln Gln
210 215 220Ser Leu Tyr Gln Asn Ala Asp Ala Tyr Val Phe Val Gly Ser
Ser Arg225 230 235 240Tyr Ser Lys Lys Phe Lys Pro Glu Ile Ala Ile
Arg Pro Lys Val Arg 245 250 255Asp Gln Glu Gly Arg Met Asn Tyr Tyr
Trp Thr Leu Val Glu Pro Gly 260 265 270Asp Lys Ile Thr Phe Glu Ala
Thr Gly Asn Leu Val Val Pro Arg Tyr 275 280 285Ala Phe Ala Met Glu
Arg Asn Ala Gly Ser Gly Ile Ile Ile Ser Asp 290 295 300Thr Pro Val
His Asp Cys Asn Thr Thr Cys Gln Thr Pro Lys Gly Ala305 310 315
320Ile Asn Thr Ser Leu Pro Phe Gln Asn Ile His Pro Ile Thr Ile Gly
325 330 335Lys Cys Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala
Thr Gly 340 345 350Leu Arg Asn Val Pro Ser Ile Gln Ser Arg Gly Leu
Phe Gly Ala Ile 355 360 365Ala Gly Phe Ile Glu Gly Gly Trp Thr Gly
Met Val Asp Gly Trp Tyr 370 375 380Gly Tyr His His Gln Asn Glu Gln
Gly Ser Gly Tyr Ala Ala Asp Leu385 390 395 400Lys Ser Thr Gln Asn
Ala Ile Asp Glu Ile Thr Asn Lys Val Asn Ser 405 410 415Val Ile Glu
Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe 420 425 430Asn
His Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp 435 440
445Gly Phe Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu
450 455 460Glu Asn Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys
Asn Leu465 470 475 480Tyr Glu Lys Val Arg Ser Gln Leu Lys Asn Asn
Ala Lys Glu Ile Gly 485 490 495Asn Gly Cys Phe Glu Phe Tyr His Lys
Cys Asp Asn Thr Cys Met Glu 500 505 510Ser Val Lys Asn Gly Thr Tyr
Asp Tyr Pro Lys Tyr Ser Glu Glu Ala 515 520 525Lys Leu Asn Arg Glu
Glu Ile Asp Gly Val Lys Leu Glu Ser Thr Arg 530 535 540Ile Tyr Gln
Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val545 550 555
560Leu Val Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly
565 570 575Ser Leu Gln Cys Arg Ile Cys Ile Tyr Pro Tyr Asp Val Pro
Asp Tyr 580 585 590Ala54739DNAArtificial SequencepGX2009
5gctgcttcgc gatgtacggg ccagatatac gcgttgacat tgattattga ctagttatta
60atagtaatca attacggggt cattagttca tagcccatat atggagttcc gcgttacata
120acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat
tgacgtcaat 180aatgacgtat gttcccatag taacgccaat agggactttc
cattgacgtc aatgggtgga 240gtatttacgg taaactgccc acttggcagt
acatcaagtg tatcatatgc caagtacgcc 300ccctattgac gtcaatgacg
gtaaatggcc cgcctggcat tatgcccagt acatgacctt 360atgggacttt
cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtgat
420gcggttttgg cagtacatca atgggcgtgg atagcggttt gactcacggg
gatttccaag 480tctccacccc attgacgtca atgggagttt gttttggcac
caaaatcaac gggactttcc 540aaaatgtcgt aacaactccg ccccattgac
gcaaatgggc ggtaggcgtg tacggtggga 600ggtctatata agcagagctc
tctggctaac tagagaaccc actgcttact ggcttatcga 660aattaatacg
actcactata gggagaccca agctggctag cgtttaaact taagcttggt
720accgagctcg gatccgccac catggactgg acctggattc tgttcctggt
ggctgctgcc 780actagagtgc acagcatgaa ggctatcctc gtcgtgctgc
tgtacacctt cgccaccgcc 840aacgccgata ccctgtgcat cggctaccac
gccaacaaca gcaccgacac cgtggatacc 900gtgctggaaa agaacgtgac
cgtgacccac agcgtgaacc tgctggaaga taagcacaac 960ggcaagctgt
gcaagctgag aggcgtggcc cctctgcacc tgggcaagtg caatatcgcc
1020ggctggattc tgggcaaccc cgagtgcgag agcctgtcta ccgctagctc
ctggtcctac 1080atcgtggaga caagcagcag cgacaacggc acctgttacc
ccggcgactt catcgactac 1140gaggaactgc gggagcagct gagcagcgtg
tccagcttcg agcggttcga gatcttcccc 1200aagaccagct cctggcccaa
ccacgacagc aacaagggcg tgaccgccgc ctgtcctcac 1260gctggcgcca
agagcttcta caagaacctg atctggctgg tcaagaaggg caacagctac
1320cccaagctga gcaagagcta catcaacgac aagggcaaag aggtcctcgt
cctctggggc 1380atccaccacc ctagcaccag cgccgaccag cagagcctgt
accagaacgc cgacgcctac 1440gtgttcgtgg gctcatctcg gtacagcaag
aagttcaagc ccgagatcgc catcagaccc 1500aaagtgcggg accaggaagg
ccggatgaac tactactgga ccctggtgga gcccggcgac 1560aagatcacct
tcgaggccac cggcaatctg gtggtgccca gatacgcctt cgccatggaa
1620agaaacgccg gcagcggcat catcatcagc gacacccccg tgcacgactg
caacaccacc 1680tgtcagaccc ccaagggcgc catcaacacc agcctgccct
tccagaacat ccaccccatc 1740accatcggca agtgccctaa gtacgtgaag
tccactaagc tcagactggc caccggcctg 1800agaaacgtgc ccagcatcca
gagcagaggc ctgtttggcg ccattgccgg ctttatcgag 1860ggcggctgga
ccggaatggt ggacgggtgg tacggctacc accaccagaa tgagcagggc
1920agcggctacg ccgccgacct gaagtccaca cagaacgcca tcgacgagat
caccaacaaa 1980gtgaacagcg tgatcgagaa gatgaacacc cagttcaccg
ccgtgggcaa agagttcaac 2040cacctggaaa agcggatcga gaacctgaac
aagaaggtgg acgacggctt cctggacatc 2100tggacctaca acgccgagct
gctggtgctg ctggaaaacg agcggaccct ggactaccac 2160gactccaacg
tgaagaatct gtacgagaaa gtgcggagcc agctgaagaa caacgccaaa
2220gagatcggca acggctgctt cgagttctac cacaagtgcg acaacacctg
tatggaaagc 2280gtgaagaacg gcacctacga ctaccccaag tacagcgagg
aagccaagct gaaccgggaa 2340gagatcgacg gcgtgaagct ggaaagcacc
cggatctacc agatcctggc catctactct 2400actgtggcca gctcactggt
gctggtggtg tccctgggcg ccatctcctt ttggatgtgc 2460tccaacggca
gcctgcagtg ccggatctgc atctacccct acgacgtgcc cgactacgcc
2520tgatgactcg agtctagagg gcccgtttaa acccgctgat cagcctcgac
tgtgccttct 2580agttgccagc catctgttgt ttgcccctcc cccgtgcctt
ccttgaccct ggaaggtgcc 2640actcccactg tcctttccta ataaaatgag
gaaattgcat cgcattgtct gagtaggtgt 2700cattctattc tggggggtgg
ggtggggcag gacagcaagg gggaggattg ggaagacaat 2760agcaggcatg
ctggggatgc ggtgggctct atggcttcta ctgggcggtt ttatggacag
2820caagcgaacc ggaattgcca gctggggcgc cctctggtaa ggttgggaag
ccctgcaaag 2880taaactggat ggctttcttg ccgccaagga tctgatggcg
caggggatca agctctgatc 2940aagagacagg atgaggatcg tttcgcatga
ttgaacaaga tggattgcac gcaggttctc 3000cggccgcttg ggtggagagg
ctattcggct atgactgggc acaacagaca atcggctgct 3060ctgatgccgc
cgtgttccgg ctgtcagcgc aggggcgccc ggttcttttt gtcaagaccg
3120acctgtccgg tgccctgaat gaactgcaag acgaggcagc gcggctatcg
tggctggcca 3180cgacgggcgt tccttgcgca gctgtgctcg acgttgtcac
tgaagcggga agggactggc 3240tgctattggg cgaagtgccg gggcaggatc
tcctgtcatc tcaccttgct cctgccgaga 3300aagtatccat catggctgat
gcaatgcggc ggctgcatac gcttgatccg gctacctgcc 3360cattcgacca
ccaagcgaaa catcgcatcg agcgagcacg tactcggatg gaagccggtc
3420ttgtcgatca ggatgatctg gacgaagagc atcaggggct cgcgccagcc
gaactgttcg 3480ccaggctcaa ggcgagcatg cccgacggcg aggatctcgt
cgtgacccat ggcgatgcct 3540gcttgccgaa tatcatggtg gaaaatggcc
gcttttctgg attcatcgac tgtggccggc 3600tgggtgtggc ggaccgctat
caggacatag cgttggctac ccgtgatatt gctgaagagc 3660ttggcggcga
atgggctgac cgcttcctcg tgctttacgg tatcgccgct cccgattcgc
3720agcgcatcgc cttctatcgc cttcttgacg agttcttctg aattattaac
gcttacaatt 3780tcctgatgcg gtattttctc cttacgcatc tgtgcggtat
ttcacaccgc atcaggtggc 3840acttttcggg gaaatgtgcg cggaacccct
atttgtttat ttttctaaat acattcaaat 3900atgtatccgc tcatgagaca
ataaccctga taaatgcttc aataatagca cgtgctaaaa 3960cttcattttt
aatttaaaag gatctaggtg aagatccttt ttgataatct catgaccaaa
4020atcccttaac gtgagttttc gttccactga gcgtcagacc ccgtagaaaa
gatcaaagga 4080tcttcttgag atcctttttt tctgcgcgta atctgctgct
tgcaaacaaa aaaaccaccg 4140ctaccagcgg tggtttgttt
gccggatcaa gagctaccaa ctctttttcc gaaggtaact 4200ggcttcagca
gagcgcagat accaaatact gttcttctag tgtagccgta gttaggccac
4260cacttcaaga actctgtagc accgcctaca tacctcgctc tgctaatcct
gttaccagtg 4320gctgctgcca gtggcgataa gtcgtgtctt accgggttgg
actcaagacg atagttaccg 4380gataaggcgc agcggtcggg ctgaacgggg
ggttcgtgca cacagcccag cttggagcga 4440acgacctaca ccgaactgag
atacctacag cgtgagctat gagaaagcgc cacgcttccc 4500gaagggagaa
aggcggacag gtatccggta agcggcaggg tcggaacagg agagcgcacg
4560agggagcttc cagggggaaa cgcctggtat ctttatagtc ctgtcgggtt
tcgccacctc 4620tgacttgagc gtcgattttt gtgatgctcg tcaggggggc
ggagcctatg gaaaaacgcc 4680agcaacgcgg cctttttacg gttcctggcc
ttttgctggc cttttgctca catgttctt 473961719DNAArtificial
SequenceInfluenza H2 antigen DNA sequence 6ggtaccaagc ttgccaccat
ggccatcatc tacctgatcc tgctgttcac cgccgtgcgg 60ggcgaccaga tctgcatcgg
ctaccacgcc aacaacagca ccgagaaggt ggacaccatc 120ctggaacgga
acgtgaccgt gacccacgcc aaggacatcc tggaaaagac ccacaacggc
180aagctgtgca agctgaacgg catccccccc ctggaactgg gcgactgcag
cattgccggc 240tggctgctgg gcaaccccga gtgcgaccgg ctgctgtccg
tgcccgagtg gagctacatc 300atggaaaaag agaacccccg ggacggcctg
tgctaccccg gcagcttcaa cgactacgag 360gaactgaagc acctgctgtc
cagcgtgaag cacttcgaga aggtgaaaat cctgcccaag 420gaccggtgga
cccagcacac caccaccggc ggcagcagag cctgtgccgt gagcggcaac
480cccagcttct tccggaacat ggtgtggctg accaagaagg gcagcaacta
ccccgtggcc 540aagggcagct acaacaacac ctccggagaa cagatgctga
tcatctgggg cgtgcaccac 600cccaacgacg agacagagca gcggaccctg
taccagaacg tgggcaccta cgtgagcgtg 660ggcaccagca ccctgaacaa
gcggagcacc cccgagatcg ccacccggcc caaggtgaac 720ggcctgggca
gccggatgga attcagctgg accctgctgg acatgtggga caccatcaac
780ttcgagagca ccggcaacct gatcgccccc gagtacggct tcaagatcag
caagcggggc 840agcagcggca tcatgaaaac cgagggcacc ctggaaaact
gcgagacaaa gtgccagacc 900cccctgggcg ccatcaacac caccctgccc
ttccacaacg tgcaccccct gaccatcggc 960gagtgcccca agtacgtgaa
gagcgagaag ctggtgctgg ccaccggcct gcggaacgtg 1020ccccagatcg
agagcagggg cctgttcggc gccattgccg gattcatcga gggcggctgg
1080cagggcatgg tggacgggtg gtacggctac caccacagca acgaccaggg
cagcggctac 1140gccgccgaca aagagagcac ccagaaggcc ttcgacggca
tcaccaacaa ggtgaacagc 1200gtgatcgaga agatgaacac ccagttcgag
gccgtgggca aagagttcag caacctggaa 1260cggcggctgg aaaacctgaa
caagaaaatg gaagatggct tcctggacgt gtggacctac 1320aacgccgagc
tgctggtgct gatggaaaac gagaggaccc tggacttcca cgacagcaac
1380gtgaagaacc tgtacgacaa agtgcggatg cagctgcggg acaacgtgaa
agagctgggc 1440aacggctgct tcgagttcta ccacaagtgc gacgacgagt
gcatgaactc cgtgaagaac 1500ggcacctacg actaccctaa gtacgaggaa
gagtccaagc tgaaccggaa cgagatcaag 1560ggcgtgaagc tgtccagcat
gggcgtgtac cagatcctgg ccatctacgc caccgtggcc 1620ggcagcctga
gcctggctat tatgatggct ggcatcagct tttggatgtg cagcaacggc
1680agcctgcagt gccggatctg catctgatga ctcgagctc
17197562PRTArtificial SequenceInfluenza H2 amino acid sequence 7Met
Ala Ile Ile Tyr Leu Ile Leu Leu Phe Thr Ala Val Arg Gly Asp1 5 10
15Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Lys Val Asp
20 25 30Thr Ile Leu Glu Arg Asn Val Thr Val Thr His Ala Lys Asp Ile
Leu 35 40 45Glu Lys Thr His Asn Gly Lys Leu Cys Lys Leu Asn Gly Ile
Pro Pro 50 55 60Leu Glu Leu Gly Asp Cys Ser Ile Ala Gly Trp Leu Leu
Gly Asn Pro65 70 75 80Glu Cys Asp Arg Leu Leu Ser Val Pro Glu Trp
Ser Tyr Ile Met Glu 85 90 95Lys Glu Asn Pro Arg Asp Gly Leu Cys Tyr
Pro Gly Ser Phe Asn Asp 100 105 110Tyr Glu Glu Leu Lys His Leu Leu
Ser Ser Val Lys His Phe Glu Lys 115 120 125Val Lys Ile Leu Pro Lys
Asp Arg Trp Thr Gln His Thr Thr Thr Gly 130 135 140Gly Ser Arg Ala
Cys Ala Val Ser Gly Asn Pro Ser Phe Phe Arg Asn145 150 155 160Met
Val Trp Leu Thr Lys Lys Gly Ser Asn Tyr Pro Val Ala Lys Gly 165 170
175Ser Tyr Asn Asn Thr Ser Gly Glu Gln Met Leu Ile Ile Trp Gly Val
180 185 190His His Pro Asn Asp Glu Thr Glu Gln Arg Thr Leu Tyr Gln
Asn Val 195 200 205Gly Thr Tyr Val Ser Val Gly Thr Ser Thr Leu Asn
Lys Arg Ser Thr 210 215 220Pro Glu Ile Ala Thr Arg Pro Lys Val Asn
Gly Leu Gly Ser Arg Met225 230 235 240Glu Phe Ser Trp Thr Leu Leu
Asp Met Trp Asp Thr Ile Asn Phe Glu 245 250 255Ser Thr Gly Asn Leu
Ile Ala Pro Glu Tyr Gly Phe Lys Ile Ser Lys 260 265 270Arg Gly Ser
Ser Gly Ile Met Lys Thr Glu Gly Thr Leu Glu Asn Cys 275 280 285Glu
Thr Lys Cys Gln Thr Pro Leu Gly Ala Ile Asn Thr Thr Leu Pro 290 295
300Phe His Asn Val His Pro Leu Thr Ile Gly Glu Cys Pro Lys Tyr
Val305 310 315 320Lys Ser Glu Lys Leu Val Leu Ala Thr Gly Leu Arg
Asn Val Pro Gln 325 330 335Ile Glu Ser Arg Gly Leu Phe Gly Ala Ile
Ala Gly Phe Ile Glu Gly 340 345 350Gly Trp Gln Gly Met Val Asp Gly
Trp Tyr Gly Tyr His His Ser Asn 355 360 365Asp Gln Gly Ser Gly Tyr
Ala Ala Asp Lys Glu Ser Thr Gln Lys Ala 370 375 380Phe Asp Gly Ile
Thr Asn Lys Val Asn Ser Val Ile Glu Lys Met Asn385 390 395 400Thr
Gln Phe Glu Ala Val Gly Lys Glu Phe Ser Asn Leu Glu Arg Arg 405 410
415Leu Glu Asn Leu Asn Lys Lys Met Glu Asp Gly Phe Leu Asp Val Trp
420 425 430Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu Asn Glu Arg
Thr Leu 435 440 445Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr Asp
Lys Val Arg Met 450 455 460Gln Leu Arg Asp Asn Val Lys Glu Leu Gly
Asn Gly Cys Phe Glu Phe465 470 475 480Tyr His Lys Cys Asp Asp Glu
Cys Met Asn Ser Val Lys Asn Gly Thr 485 490 495Tyr Asp Tyr Pro Lys
Tyr Glu Glu Glu Ser Lys Leu Asn Arg Asn Glu 500 505 510Ile Lys Gly
Val Lys Leu Ser Ser Met Gly Val Tyr Gln Ile Leu Ala 515 520 525Ile
Tyr Ala Thr Val Ala Gly Ser Leu Ser Leu Ala Ile Met Met Ala 530 535
540Gly Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu Gln Cys Arg
Ile545 550 555 560Cys Ile84628DNAArtificial SequencepGX2006 DNA
sequence 8gactcttcgc gatgtacggg ccagatatac gcgttgacat tgattattga
ctagttatta 60atagtaatca attacggggt cattagttca tagcccatat atggagttcc
gcgttacata 120acttacggta aatggcccgc ctggctgacc gcccaacgac
ccccgcccat tgacgtcaat 180aatgacgtat gttcccatag taacgccaat
agggactttc cattgacgtc aatgggtgga 240gtatttacgg taaactgccc
acttggcagt acatcaagtg tatcatatgc caagtacgcc 300ccctattgac
gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt
360atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta
ccatggtgat 420gcggttttgg cagtacatca atgggcgtgg atagcggttt
gactcacggg gatttccaag 480tctccacccc attgacgtca atgggagttt
gttttggcac caaaatcaac gggactttcc 540aaaatgtcgt aacaactccg
ccccattgac gcaaatgggc ggtaggcgtg tacggtggga 600ggtctatata
agcagagctc tctggctaac tagagaaccc actgcttact ggcttatcga
660aattaatacg actcactata gggagaccca agctggctag cgtttaaact
taagcttgcc 720accatggcca tcatctacct gatcctgctg ttcaccgccg
tgcggggcga ccagatctgc 780atcggctacc acgccaacaa cagcaccgag
aaggtggaca ccatcctgga acggaacgtg 840accgtgaccc acgccaagga
catcctggaa aagacccaca acggcaagct gtgcaagctg 900aacggcatcc
cccccctgga actgggcgac tgcagcattg ccggctggct gctgggcaac
960cccgagtgcg accggctgct gtccgtgccc gagtggagct acatcatgga
aaaagagaac 1020ccccgggacg gcctgtgcta ccccggcagc ttcaacgact
acgaggaact gaagcacctg 1080ctgtccagcg tgaagcactt cgagaaggtg
aaaatcctgc ccaaggaccg gtggacccag 1140cacaccacca ccggcggcag
cagagcctgt gccgtgagcg gcaaccccag cttcttccgg 1200aacatggtgt
ggctgaccaa gaagggcagc aactaccccg tggccaaggg cagctacaac
1260aacacctccg gagaacagat gctgatcatc tggggcgtgc accaccccaa
cgacgagaca 1320gagcagcgga ccctgtacca gaacgtgggc acctacgtga
gcgtgggcac cagcaccctg 1380aacaagcgga gcacccccga gatcgccacc
cggcccaagg tgaacggcct gggcagccgg 1440atggaattca gctggaccct
gctggacatg tgggacacca tcaacttcga gagcaccggc 1500aacctgatcg
cccccgagta cggcttcaag atcagcaagc ggggcagcag cggcatcatg
1560aaaaccgagg gcaccctgga aaactgcgag acaaagtgcc agacccccct
gggcgccatc 1620aacaccaccc tgcccttcca caacgtgcac cccctgacca
tcggcgagtg ccccaagtac 1680gtgaagagcg agaagctggt gctggccacc
ggcctgcgga acgtgcccca gatcgagagc 1740aggggcctgt tcggcgccat
tgccggattc atcgagggcg gctggcaggg catggtggac 1800gggtggtacg
gctaccacca cagcaacgac cagggcagcg gctacgccgc cgacaaagag
1860agcacccaga aggccttcga cggcatcacc aacaaggtga acagcgtgat
cgagaagatg 1920aacacccagt tcgaggccgt gggcaaagag ttcagcaacc
tggaacggcg gctggaaaac 1980ctgaacaaga aaatggaaga tggcttcctg
gacgtgtgga cctacaacgc cgagctgctg 2040gtgctgatgg aaaacgagag
gaccctggac ttccacgaca gcaacgtgaa gaacctgtac 2100gacaaagtgc
ggatgcagct gcgggacaac gtgaaagagc tgggcaacgg ctgcttcgag
2160ttctaccaca agtgcgacga cgagtgcatg aactccgtga agaacggcac
ctacgactac 2220cctaagtacg aggaagagtc caagctgaac cggaacgaga
tcaagggcgt gaagctgtcc 2280agcatgggcg tgtaccagat cctggccatc
tacgccaccg tggccggcag cctgagcctg 2340gctattatga tggctggcat
cagcttttgg atgtgcagca acggcagcct gcagtgccgg 2400atctgcatct
gatgactcga gtctagaggg cccgtttaaa cccgctgatc agcctcgact
2460gtgccttcta gttgccagcc atctgttgtt tgcccctccc ccgtgccttc
cttgaccctg 2520gaaggtgcca ctcccactgt cctttcctaa taaaatgagg
aaattgcatc gcattgtctg 2580agtaggtgtc attctattct ggggggtggg
gtggggcagg acagcaaggg ggaggattgg 2640gaagacaata gcaggcatgc
tggggatgcg gtgggctcta tggcttctac tgggcggttt 2700tatggacagc
aagcgaaccg gaattgccag ctggggcgcc ctctggtaag gttgggaagc
2760cctgcaaagt aaactggatg gctttcttgc cgccaaggat ctgatggcgc
aggggatcaa 2820gctctgatca agagacagga tgaggatcgt ttcgcatgat
tgaacaagat ggattgcacg 2880caggttctcc ggccgcttgg gtggagaggc
tattcggcta tgactgggca caacagacaa 2940tcggctgctc tgatgccgcc
gtgttccggc tgtcagcgca ggggcgcccg gttctttttg 3000tcaagaccga
cctgtccggt gccctgaatg aactgcaaga cgaggcagcg cggctatcgt
3060ggctggccac gacgggcgtt ccttgcgcag ctgtgctcga cgttgtcact
gaagcgggaa 3120gggactggct gctattgggc gaagtgccgg ggcaggatct
cctgtcatct caccttgctc 3180ctgccgagaa agtatccatc atggctgatg
caatgcggcg gctgcatacg cttgatccgg 3240ctacctgccc attcgaccac
caagcgaaac atcgcatcga gcgagcacgt actcggatgg 3300aagccggtct
tgtcgatcag gatgatctgg acgaagagca tcaggggctc gcgccagccg
3360aactgttcgc caggctcaag gcgagcatgc ccgacggcga ggatctcgtc
gtgacccatg 3420gcgatgcctg cttgccgaat atcatggtgg aaaatggccg
cttttctgga ttcatcgact 3480gtggccggct gggtgtggcg gaccgctatc
aggacatagc gttggctacc cgtgatattg 3540ctgaagagct tggcggcgaa
tgggctgacc gcttcctcgt gctttacggt atcgccgctc 3600ccgattcgca
gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga attattaacg
3660cttacaattt cctgatgcgg tattttctcc ttacgcatct gtgcggtatt
tcacaccgca 3720tcaggtggca cttttcgggg aaatgtgcgc ggaaccccta
tttgtttatt tttctaaata 3780cattcaaata tgtatccgct catgagacaa
taaccctgat aaatgcttca ataatagcac 3840gtgctaaaac ttcattttta
atttaaaagg atctaggtga agatcctttt tgataatctc 3900atgaccaaaa
tcccttaacg tgagttttcg ttccactgag cgtcagaccc cgtagaaaag
3960atcaaaggat cttcttgaga tccttttttt ctgcgcgtaa tctgctgctt
gcaaacaaaa 4020aaaccaccgc taccagcggt ggtttgtttg ccggatcaag
agctaccaac tctttttccg 4080aaggtaactg gcttcagcag agcgcagata
ccaaatactg ttcttctagt gtagccgtag 4140ttaggccacc acttcaagaa
ctctgtagca ccgcctacat acctcgctct gctaatcctg 4200ttaccagtgg
ctgctgccag tggcgataag tcgtgtctta ccgggttgga ctcaagacga
4260tagttaccgg ataaggcgca gcggtcgggc tgaacggggg gttcgtgcac
acagcccagc 4320ttggagcgaa cgacctacac cgaactgaga tacctacagc
gtgagctatg agaaagcgcc 4380acgcttcccg aagggagaaa ggcggacagg
tatccggtaa gcggcagggt cggaacagga 4440gagcgcacga gggagcttcc
agggggaaac gcctggtatc tttatagtcc tgtcgggttt 4500cgccacctct
gacttgagcg tcgatttttg tgatgctcgt caggggggcg gagcctatgg
4560aaaaacgcca gcaacgcggc ctttttacgg ttcctggcct tttgctggcc
ttttgctcac 4620atgttctt 462891695DNAArtificial SequenceInfluenza U2
DNA sequence 9aaggccaagc tgctggtgct gctgtgcacc ttcgccgcca
ccaacgccga caccatctgc 60atcggctacc acgccaacaa cagcaccgac accgtggata
ccgtgctgga aaagaacgtg 120accgtgaccc acagcgtgaa cctgctggaa
gataagcaca acggcaagct gtgcaagctg 180aagggaatcg cccccctgca
gctgggcaag tgcaatatcg ccggctggat tctgggcaac 240cccgagtgcg
agagcctgag cagcaagagc agctggtcct acatcgtgga aacccccaac
300agcgagaacg gcacctgtta ccccggcgac ttcgccgact acgaggaact
gcgcgagcag 360ctgagcagcg tgtccagctt cgagagattc gagatcttcc
ccaagaccag cagctggccc 420aaccacgacg tgaccaaggg cgtgaccgct
agctgtagcc acgcaggcgc cagcagcttc 480tacaagaacc tgctgtggct
gaccaagaag aacggcagct accccaagct gagcaagagc 540tacatcaaca
acaaagaaaa agaggtgctg gtcctctggg gcgtccacca ccccagcaca
600atcgccgacc agcagagcct gtaccagaac gagaacgcct acgtgtccgt
gggcagcagc 660cactacagcc ggaagttcac ccccgagatc gccaagcggc
ccaaagtgcg ggaccaggaa 720ggccggatca actactactg gaccctgctg
gaacccggcg acaccatcat cttcgaggcc 780aacggcaacc tgatcgcccc
cagatacgcc ttcgccctga gcagaggctt cggcagcggc 840atcatcatca
gcaacgcccc catgcacgac tgcgacacca agtgccagac ccctcagggc
900gccatcaaca gcagcctgcc cttccagaac atccaccccg tgaccatcgg
cgagtgcccc 960aaatacgtgc ggagcaccaa gctgcggatg gccaccggcc
tgcggaacat ccccagcatc 1020cagagcagag gcctgttcgg cgccattgcc
ggcttcatcg agggcggctg gaccggaatg 1080gtggacgggt ggtacggcta
ccaccaccag aatgagcagg gcagcggcta cgccgccgac 1140cagaagtcca
cccagaacgc catcgacggc atcaccaaca aagtgaacag cgtgatcgag
1200aagatgaaca cccagttcac cgccgtgggc aaagagttca acaagctgga
aaagcggatg 1260gaaaacctga acaagaaggt ggacgacggc ttcctggaca
tctggaccta caacgccgaa 1320ctgctcgtgc tgctggaaaa cgagcggacc
ctggacttcc acgacagcaa cgtgaagaac 1380ctgtacgaga aagtgaagtc
ccagctgaag aacaacgcca aagagatcgg caacggctgc 1440ttcgagttct
accacaagtg caacaacgag tgcatggaaa gcgtgaagaa cggaacctac
1500gactacccca agtacagcga ggaaagcaag ctgaaccggg aagagatcga
cggcgtgaag 1560ctggaatcca tgggcgtgta ccagatcctg gccatctaca
gcaccgtggc tagcagcctg 1620gtgctgctgg tgtccctggg cgccatctcc
ttttggatgt gctccaacgg cagcctgcag 1680tgccggatct gcatc
169510565PRTArtificial SequenceInfluenza U2 amino acid sequence
10Lys Ala Lys Leu Leu Val Leu Leu Cys Thr Phe Ala Ala Thr Asn Ala1
5 10 15Asp Thr Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr
Val 20 25 30Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val
Asn Leu 35 40 45Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Lys
Gly Ile Ala 50 55 60Pro Leu Gln Leu Gly Lys Cys Asn Ile Ala Gly Trp
Ile Leu Gly Asn65 70 75 80Pro Glu Cys Glu Ser Leu Ser Ser Lys Ser
Ser Trp Ser Tyr Ile Val 85 90 95Glu Thr Pro Asn Ser Glu Asn Gly Thr
Cys Tyr Pro Gly Asp Phe Ala 100 105 110Asp Tyr Glu Glu Leu Arg Glu
Gln Leu Ser Ser Val Ser Ser Phe Glu 115 120 125Arg Phe Glu Ile Phe
Pro Lys Thr Ser Ser Trp Pro Asn His Asp Val 130 135 140Thr Lys Gly
Val Thr Ala Ser Cys Ser His Ala Gly Ala Ser Ser Phe145 150 155
160Tyr Lys Asn Leu Leu Trp Leu Thr Lys Lys Asn Gly Ser Tyr Pro Lys
165 170 175Leu Ser Lys Ser Tyr Ile Asn Asn Lys Glu Lys Glu Val Leu
Val Leu 180 185 190Trp Gly Val His His Pro Ser Thr Ile Ala Asp Gln
Gln Ser Leu Tyr 195 200 205Gln Asn Glu Asn Ala Tyr Val Ser Val Gly
Ser Ser His Tyr Ser Arg 210 215 220Lys Phe Thr Pro Glu Ile Ala Lys
Arg Pro Lys Val Arg Asp Gln Glu225 230 235 240Gly Arg Ile Asn Tyr
Tyr Trp Thr Leu Leu Glu Pro Gly Asp Thr Ile 245 250 255Ile Phe Glu
Ala Asn Gly Asn Leu Ile Ala Pro Arg Tyr Ala Phe Ala 260 265 270Leu
Ser Arg Gly Phe Gly Ser Gly Ile Ile Ile Ser Asn Ala Pro Met 275 280
285His Asp Cys Asp Thr Lys Cys Gln Thr Pro Gln Gly Ala Ile Asn Ser
290 295 300Ser Leu Pro Phe Gln Asn Ile His Pro Val Thr Ile Gly Glu
Cys Pro305 310 315 320Lys Tyr Val Arg Ser Thr Lys Leu Arg Met Ala
Thr Gly Leu Arg Asn 325 330 335Ile Pro Ser Ile Gln Ser Arg Gly Leu
Phe Gly Ala Ile Ala Gly Phe 340 345 350Ile Glu Gly Gly Trp Thr Gly
Met Val Asp Gly Trp Tyr Gly Tyr His 355 360 365His Gln Asn Glu Gln
Gly Ser Gly Tyr Ala Ala Asp Gln Lys Ser Thr 370 375 380Gln Asn Ala
Ile Asp Gly Ile Thr Asn Lys Val Asn Ser Val Ile Glu385 390 395
400Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn Lys Leu
405 410 415Glu Lys Arg Met Glu Asn Leu Asn Lys Lys Val Asp Asp Gly
Phe Leu 420 425 430Asp Ile Trp Thr Tyr Asn
Ala Glu Leu Leu Val Leu Leu Glu Asn Glu 435 440 445Arg Thr Leu Asp
Phe His Asp Ser Asn Val Lys Asn Leu Tyr Glu Lys 450 455 460Val Lys
Ser Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly Cys465 470 475
480Phe Glu Phe Tyr His Lys Cys Asn Asn Glu Cys Met Glu Ser Val Lys
485 490 495Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ser Lys
Leu Asn 500 505 510Arg Glu Glu Ile Asp Gly Val Lys Leu Glu Ser Met
Gly Val Tyr Gln 515 520 525Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser
Ser Leu Val Leu Leu Val 530 535 540Ser Leu Gly Ala Ile Ser Phe Trp
Met Cys Ser Asn Gly Ser Leu Gln545 550 555 560Cys Arg Ile Cys Ile
565111809DNAArtificial SequenceIgE-U2-HATAntigen DNA Sequence
11ggtaccggat ccgccaccat ggactggacc tggattctgt tcctggtcgc cgctgctacc
60cgggtgcact ctaaggccaa gctgctggtg ctgctgtgca ccttcgccgc caccaacgcc
120gacaccatct gcatcggcta ccacgccaac aacagcaccg acaccgtgga
taccgtgctg 180gaaaagaacg tgaccgtgac ccacagcgtg aacctgctgg
aagataagca caacggcaag 240ctgtgcaagc tgaagggaat cgcccccctg
cagctgggca agtgcaatat cgccggctgg 300attctgggca accccgagtg
cgagagcctg agcagcaaga gcagctggtc ctacatcgtg 360gaaaccccca
acagcgagaa cggcacctgt taccccggcg acttcgccga ctacgaggaa
420ctgcgcgagc agctgagcag cgtgtccagc ttcgagagat tcgagatctt
ccccaagacc 480agcagctggc ccaaccacga cgtgaccaag ggcgtgaccg
ctagctgtag ccacgcaggc 540gccagcagct tctacaagaa cctgctgtgg
ctgaccaaga agaacggcag ctaccccaag 600ctgagcaaga gctacatcaa
caacaaagaa aaagaggtgc tggtcctctg gggcgtccac 660caccccagca
caatcgccga ccagcagagc ctgtaccaga acgagaacgc ctacgtgtcc
720gtgggcagca gccactacag ccggaagttc acccccgaga tcgccaagcg
gcccaaagtg 780cgggaccagg aaggccggat caactactac tggaccctgc
tggaacccgg cgacaccatc 840atcttcgagg ccaacggcaa cctgatcgcc
cccagatacg ccttcgccct gagcagaggc 900ttcggcagcg gcatcatcat
cagcaacgcc cccatgcacg actgcgacac caagtgccag 960acccctcagg
gcgccatcaa cagcagcctg cccttccaga acatccaccc cgtgaccatc
1020ggcgagtgcc ccaaatacgt gcggagcacc aagctgcgga tggccaccgg
cctgcggaac 1080atccccagca tccagagcag aggcctgttc ggcgccattg
ccggcttcat cgagggcggc 1140tggaccggaa tggtggacgg gtggtacggc
taccaccacc agaatgagca gggcagcggc 1200tacgccgccg accagaagtc
cacccagaac gccatcgacg gcatcaccaa caaagtgaac 1260agcgtgatcg
agaagatgaa cacccagttc accgccgtgg gcaaagagtt caacaagctg
1320gaaaagcgga tggaaaacct gaacaagaag gtggacgacg gcttcctgga
catctggacc 1380tacaacgccg aactgctcgt gctgctggaa aacgagcgga
ccctggactt ccacgacagc 1440aacgtgaaga acctgtacga gaaagtgaag
tcccagctga agaacaacgc caaagagatc 1500ggcaacggct gcttcgagtt
ctaccacaag tgcaacaacg agtgcatgga aagcgtgaag 1560aacggaacct
acgactaccc caagtacagc gaggaaagca agctgaaccg ggaagagatc
1620gacggcgtga agctggaatc catgggcgtg taccagatcc tggccatcta
cagcaccgtg 1680gctagcagcc tggtgctgct ggtgtccctg ggcgccatct
ccttttggat gtgctccaac 1740ggcagcctgc agtgccggat ctgcatctac
ccctacgacg tgcccgacta cgcctgatga 1800ctcgagctc
180912592PRTArtificial SequenceIgE-U2-HATantigen amino acid
Sequence 12Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr
Arg Val1 5 10 15His Ser Lys Ala Lys Leu Leu Val Leu Leu Cys Thr Phe
Ala Ala Thr 20 25 30Asn Ala Asp Thr Ile Cys Ile Gly Tyr His Ala Asn
Asn Ser Thr Asp 35 40 45Thr Val Asp Thr Val Leu Glu Lys Asn Val Thr
Val Thr His Ser Val 50 55 60Asn Leu Leu Glu Asp Lys His Asn Gly Lys
Leu Cys Lys Leu Lys Gly65 70 75 80Ile Ala Pro Leu Gln Leu Gly Lys
Cys Asn Ile Ala Gly Trp Ile Leu 85 90 95Gly Asn Pro Glu Cys Glu Ser
Leu Ser Ser Lys Ser Ser Trp Ser Tyr 100 105 110Ile Val Glu Thr Pro
Asn Ser Glu Asn Gly Thr Cys Tyr Pro Gly Asp 115 120 125Phe Ala Asp
Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser 130 135 140Phe
Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His145 150
155 160Asp Val Thr Lys Gly Val Thr Ala Ser Cys Ser His Ala Gly Ala
Ser 165 170 175Ser Phe Tyr Lys Asn Leu Leu Trp Leu Thr Lys Lys Asn
Gly Ser Tyr 180 185 190Pro Lys Leu Ser Lys Ser Tyr Ile Asn Asn Lys
Glu Lys Glu Val Leu 195 200 205Val Leu Trp Gly Val His His Pro Ser
Thr Ile Ala Asp Gln Gln Ser 210 215 220Leu Tyr Gln Asn Glu Asn Ala
Tyr Val Ser Val Gly Ser Ser His Tyr225 230 235 240Ser Arg Lys Phe
Thr Pro Glu Ile Ala Lys Arg Pro Lys Val Arg Asp 245 250 255Gln Glu
Gly Arg Ile Asn Tyr Tyr Trp Thr Leu Leu Glu Pro Gly Asp 260 265
270Thr Ile Ile Phe Glu Ala Asn Gly Asn Leu Ile Ala Pro Arg Tyr Ala
275 280 285Phe Ala Leu Ser Arg Gly Phe Gly Ser Gly Ile Ile Ile Ser
Asn Ala 290 295 300Pro Met His Asp Cys Asp Thr Lys Cys Gln Thr Pro
Gln Gly Ala Ile305 310 315 320Asn Ser Ser Leu Pro Phe Gln Asn Ile
His Pro Val Thr Ile Gly Glu 325 330 335Cys Pro Lys Tyr Val Arg Ser
Thr Lys Leu Arg Met Ala Thr Gly Leu 340 345 350Arg Asn Ile Pro Ser
Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala 355 360 365Gly Phe Ile
Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp Tyr Gly 370 375 380Tyr
His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Gln Lys385 390
395 400Ser Thr Gln Asn Ala Ile Asp Gly Ile Thr Asn Lys Val Asn Ser
Val 405 410 415Ile Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys
Glu Phe Asn 420 425 430Lys Leu Glu Lys Arg Met Glu Asn Leu Asn Lys
Lys Val Asp Asp Gly 435 440 445Phe Leu Asp Ile Trp Thr Tyr Asn Ala
Glu Leu Leu Val Leu Leu Glu 450 455 460Asn Glu Arg Thr Leu Asp Phe
His Asp Ser Asn Val Lys Asn Leu Tyr465 470 475 480Glu Lys Val Lys
Ser Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn 485 490 495Gly Cys
Phe Glu Phe Tyr His Lys Cys Asn Asn Glu Cys Met Glu Ser 500 505
510Val Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ser Lys
515 520 525Leu Asn Arg Glu Glu Ile Asp Gly Val Lys Leu Glu Ser Met
Gly Val 530 535 540Tyr Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser
Ser Leu Val Leu545 550 555 560Leu Val Ser Leu Gly Ala Ile Ser Phe
Trp Met Cys Ser Asn Gly Ser 565 570 575Leu Gln Cys Arg Ile Cys Ile
Tyr Pro Tyr Asp Val Pro Asp Tyr Ala 580 585 590131749DNAArtificial
SequenceBHA DNA Sequence 13aaggccatca tcgtgctgct gatggtggtc
acaagcaacg ccgaccggat ctgcaccggc 60atcaccagca gcaacagccc ccacgtggtc
aaaaccgcca cccagggcga agtgaacgtg 120accggcgtga tccccctgac
caccaccccc accaagagcc acttcgccaa cctgaagggc 180accaagaccc
ggggaaagct gtgccccaag tgcctgaact gcaccgacct ggacgtggcc
240ctgggcagac ctatgtgcgt gggcaccacc cctagcgcca aggccagcat
cctgcacgaa 300gtgcggcccg tgaccagcgg ctgcttcccc atcatgcacg
accggaccaa gatccggcag 360ctccccaacc tgctgcgggg ctacgagaac
atccggctga gcacccagaa cgtgatcaac 420gccgagaagg cccctggcgg
cccttacaga ctgggcacaa gcggctcttg ccccaacgcc 480accagcaaga
gcggcttttt cgccacaatg gcctgggccg tgcccaagga caacaacaag
540accgccacca accccctgac cgtggaagtg ccctacatct gcaccgaggg
cgaggaccag 600atcaccgtgt ggggcttcca cagcgataac aagacccaga
tgaagaacct gtacggcgac 660agcaaccccc agaagttcac cagctccgcc
aacggcgtga ccacccacta cgtgtcccag 720atcggcggct tccccgacca
gacagaggat ggcggcctgc cccagagcgg cagaatcgtg 780gtggactaca
tggtgcagaa gcccggcaag accggcacca tcgtgtacca gcggggcatc
840ctgctgcccc agaaagtgtg gtgcgccagc ggccggtcca aagtgatcaa
gggcagcctg 900cctctgatcg gcgaggccga ttgcctgcac gagaagtacg
gcggcctgaa caagagcaag 960ccctactaca ccggcgagca cgccaaagcc
atcggcaact gccccatctg ggtcaaaacc 1020cccctgaagc tggccaacgg
caccaagtac cggcctcccg ccaagctgct gaaagagcgg 1080ggcttcttcg
gcgctatcgc cggctttctg gaaggcggct gggagggcat gatcgccggc
1140tggcacggct acacatctca cggcgctcat ggcgtggccg tggccgctga
tctgaagtcc 1200acccaggaag ccatcaacaa gatcaccaag aacctgaaca
gcctgagcga gctggaagtg 1260aagaatctgc agcggctgag cggcgccatg
gacgagctgc acaacgagat cctggaactg 1320gacgagaagg tggacgacct
gcgggccgac accatctcca gccagatcga gctggccgtg 1380ctgctgtcca
acgagggcat catcaacagc gaggacgagc atctgctggc cctggaacgg
1440aagctgaaga agatgctggg ccctagcgcc gtggacatcg gcaacggctg
cttcgagaca 1500aagcacaagt gcaaccagac ctgcctggac cggatcgctg
ccggcacctt caacgccggc 1560gagttcagcc tgcccacctt cgacagcctg
aacatcaccg ccgccagcct gaacgacgac 1620ggcctggaca accacaccat
cctgctgtac tacagcaccg cagcctccag cctggccgtg 1680accctgatga
tcgccatctt catcgtgtac atggtgtctc gggacaacgt gtcctgcagc
1740atctgcctg 174914583PRTArtificial SequenceBHA Amino Acid
Sequence 14Lys Ala Ile Ile Val Leu Leu Met Val Val Thr Ser Asn Ala
Asp Arg1 5 10 15Ile Cys Thr Gly Ile Thr Ser Ser Asn Ser Pro His Val
Val Lys Thr 20 25 30Ala Thr Gln Gly Glu Val Asn Val Thr Gly Val Ile
Pro Leu Thr Thr 35 40 45Thr Pro Thr Lys Ser His Phe Ala Asn Leu Lys
Gly Thr Lys Thr Arg 50 55 60Gly Lys Leu Cys Pro Lys Cys Leu Asn Cys
Thr Asp Leu Asp Val Ala65 70 75 80Leu Gly Arg Pro Met Cys Val Gly
Thr Thr Pro Ser Ala Lys Ala Ser 85 90 95Ile Leu His Glu Val Arg Pro
Val Thr Ser Gly Cys Phe Pro Ile Met 100 105 110His Asp Arg Thr Lys
Ile Arg Gln Leu Pro Asn Leu Leu Arg Gly Tyr 115 120 125Glu Asn Ile
Arg Leu Ser Thr Gln Asn Val Ile Asn Ala Glu Lys Ala 130 135 140Pro
Gly Gly Pro Tyr Arg Leu Gly Thr Ser Gly Ser Cys Pro Asn Ala145 150
155 160Thr Ser Lys Ser Gly Phe Phe Ala Thr Met Ala Trp Ala Val Pro
Lys 165 170 175Asp Asn Asn Lys Thr Ala Thr Asn Pro Leu Thr Val Glu
Val Pro Tyr 180 185 190Ile Cys Thr Glu Gly Glu Asp Gln Ile Thr Val
Trp Gly Phe His Ser 195 200 205Asp Asn Lys Thr Gln Met Lys Asn Leu
Tyr Gly Asp Ser Asn Pro Gln 210 215 220Lys Phe Thr Ser Ser Ala Asn
Gly Val Thr Thr His Tyr Val Ser Gln225 230 235 240Ile Gly Gly Phe
Pro Asp Gln Thr Glu Asp Gly Gly Leu Pro Gln Ser 245 250 255Gly Arg
Ile Val Val Asp Tyr Met Val Gln Lys Pro Gly Lys Thr Gly 260 265
270Thr Ile Val Tyr Gln Arg Gly Ile Leu Leu Pro Gln Lys Val Trp Cys
275 280 285Ala Ser Gly Arg Ser Lys Val Ile Lys Gly Ser Leu Pro Leu
Ile Gly 290 295 300Glu Ala Asp Cys Leu His Glu Lys Tyr Gly Gly Leu
Asn Lys Ser Lys305 310 315 320Pro Tyr Tyr Thr Gly Glu His Ala Lys
Ala Ile Gly Asn Cys Pro Ile 325 330 335Trp Val Lys Thr Pro Leu Lys
Leu Ala Asn Gly Thr Lys Tyr Arg Pro 340 345 350Pro Ala Lys Leu Leu
Lys Glu Arg Gly Phe Phe Gly Ala Ile Ala Gly 355 360 365Phe Leu Glu
Gly Gly Trp Glu Gly Met Ile Ala Gly Trp His Gly Tyr 370 375 380Thr
Ser His Gly Ala His Gly Val Ala Val Ala Ala Asp Leu Lys Ser385 390
395 400Thr Gln Glu Ala Ile Asn Lys Ile Thr Lys Asn Leu Asn Ser Leu
Ser 405 410 415Glu Leu Glu Val Lys Asn Leu Gln Arg Leu Ser Gly Ala
Met Asp Glu 420 425 430Leu His Asn Glu Ile Leu Glu Leu Asp Glu Lys
Val Asp Asp Leu Arg 435 440 445Ala Asp Thr Ile Ser Ser Gln Ile Glu
Leu Ala Val Leu Leu Ser Asn 450 455 460Glu Gly Ile Ile Asn Ser Glu
Asp Glu His Leu Leu Ala Leu Glu Arg465 470 475 480Lys Leu Lys Lys
Met Leu Gly Pro Ser Ala Val Asp Ile Gly Asn Gly 485 490 495Cys Phe
Glu Thr Lys His Lys Cys Asn Gln Thr Cys Leu Asp Arg Ile 500 505
510Ala Ala Gly Thr Phe Asn Ala Gly Glu Phe Ser Leu Pro Thr Phe Asp
515 520 525Ser Leu Asn Ile Thr Ala Ala Ser Leu Asn Asp Asp Gly Leu
Asp Asn 530 535 540His Thr Ile Leu Leu Tyr Tyr Ser Thr Ala Ala Ser
Ser Leu Ala Val545 550 555 560Thr Leu Met Ile Ala Ile Phe Ile Val
Tyr Met Val Ser Arg Asp Asn 565 570 575Val Ser Cys Ser Ile Cys Leu
580151865DNAArtificial SequenceIgE-BHA-HATantigen DNA Sequence
15ggtaccggat ccgccaccat ggactggacc tggattctgt tcctggtggc cgctgccaca
60cgggtgcaca gcaaggccat catcgtgctg ctgatggtgg tcacaagcaa cgccgaccgg
120atctgcaccg gcatcaccag cagcaacagc ccccacgtgg tcaaaaccgc
cacccagggc 180gaagtgaacg tgaccggcgt gatccccctg accaccaccc
ccaccaagag ccacttcgcc 240aacctgaagg gcaccaagac ccggggaaag
ctgtgcccca agtgcctgaa ctgcaccgac 300ctggacgtgg ccctgggcag
acctatgtgc gtgggcacca cccctagcgc caaggccagc 360atcctgcacg
aagtgcggcc cgtgaccagc ggctgcttcc ccatcatgca cgaccggacc
420aagatccggc agctccccaa cctgctgcgg ggctacgaga acatccggct
gagcacccag 480aacgtgatca acgccgagaa ggcccctggc ggcccttaca
gactgggcac aagcggctct 540tgccccaacg ccaccagcaa gagcggcttt
ttcgccacaa tggcctgggc cgtgcccaag 600gacaacaaca agaccgccac
caaccccctg accgtggaag tgccctacat ctgcaccgag 660ggcgaggacc
agatcaccgt gtggggcttc cacagcgata acaagaccca gatgaagaac
720ctgtacggcg acagcaaccc ccagaagttc accagctccg ccaacggcgt
gaccacccac 780tacgtgtccc agatcggcgg cttccccgac cagacagagg
atggcggcct gccccagagc 840ggcagaatcg tggtggacta catggtgcag
aagcccggca agaccggcac catcgtgtac 900cagcggggca tcctgctgcc
ccagaaagtg tggtgcgcca gcggccggtc caaagtgatc 960aagggcagcc
tgcctctgat cggcgaggcc gattgcctgc acgagaagta cggcggcctg
1020aacaagagca agccctacta caccggcgag cacgccaaag ccatcggcaa
ctgccccatc 1080tgggtcaaaa cccccctgaa gctggccaac ggcaccaagt
accggcctcc cgccaagctg 1140ctgaaagagc ggggcttctt cggcgctatc
gccggctttc tggaaggcgg ctgggagggc 1200atgatcgccg gctggcacgg
ctacacatct cacggcgctc atggcgtggc cgtggccgct 1260gatctgaagt
ccacccagga agccatcaac aagatcacca agaacctgaa cagcctgagc
1320gagctggaag tgaagaatct gcagcggctg agcggcgcca tggacgagct
gcacaacgag 1380atcctggaac tggacgagaa ggtggacgac ctgcgggccg
acaccatctc cagccagatc 1440gagctggccg tgctgctgtc caacgagggc
atcatcaaca gcgaggacga gcatctgctg 1500gccctggaac ggaagctgaa
gaagatgctg ggccctagcg ccgtggacat cggcaacggc 1560tgcttcgaga
caaagcacaa gtgcaaccag acctgcctgg accggatcgc tgccggcacc
1620ttcaacgccg gcgagttcag cctgcccacc ttcgacagcc tgaacatcac
cgccgccagc 1680ctgaacgacg acggcctgga caaccacacc atcctgctgt
actacagcac cgcagcctcc 1740agcctggccg tgaccctgat gatcgccatc
ttcatcgtgt acatggtgtc tcgggacaac 1800gtgtcctgca gcatctgcct
gtacccctac gacgtgcccg actacgctga tgactcgagc 1860tcctc
186516610PRTArtificial SequenceIgE-BHA-HATantigen Amino Acid
Sequence 16Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr
Arg Val1 5 10 15His Ser Lys Ala Ile Ile Val Leu Leu Met Val Val Thr
Ser Asn Ala 20 25 30Asp Arg Ile Cys Thr Gly Ile Thr Ser Ser Asn Ser
Pro His Val Val 35 40 45Lys Thr Ala Thr Gln Gly Glu Val Asn Val Thr
Gly Val Ile Pro Leu 50 55 60Thr Thr Thr Pro Thr Lys Ser His Phe Ala
Asn Leu Lys Gly Thr Lys65 70 75 80Thr Arg Gly Lys Leu Cys Pro Lys
Cys Leu Asn Cys Thr Asp Leu Asp 85 90 95Val Ala Leu Gly Arg Pro Met
Cys Val Gly Thr Thr Pro Ser Ala Lys 100 105 110Ala Ser Ile Leu His
Glu Val Arg Pro Val Thr Ser Gly Cys Phe Pro 115 120 125Ile Met His
Asp Arg Thr Lys Ile Arg Gln Leu Pro Asn Leu Leu Arg 130 135 140Gly
Tyr Glu Asn Ile Arg Leu Ser Thr Gln Asn Val Ile Asn Ala Glu145 150
155 160Lys Ala Pro Gly Gly Pro Tyr Arg Leu Gly Thr Ser Gly Ser Cys
Pro 165 170 175Asn Ala Thr Ser Lys Ser Gly Phe Phe Ala Thr Met Ala
Trp Ala Val 180 185 190Pro Lys Asp Asn Asn Lys Thr Ala Thr Asn Pro
Leu Thr Val
Glu Val 195 200 205Pro Tyr Ile Cys Thr Glu Gly Glu Asp Gln Ile Thr
Val Trp Gly Phe 210 215 220His Ser Asp Asn Lys Thr Gln Met Lys Asn
Leu Tyr Gly Asp Ser Asn225 230 235 240Pro Gln Lys Phe Thr Ser Ser
Ala Asn Gly Val Thr Thr His Tyr Val 245 250 255Ser Gln Ile Gly Gly
Phe Pro Asp Gln Thr Glu Asp Gly Gly Leu Pro 260 265 270Gln Ser Gly
Arg Ile Val Val Asp Tyr Met Val Gln Lys Pro Gly Lys 275 280 285Thr
Gly Thr Ile Val Tyr Gln Arg Gly Ile Leu Leu Pro Gln Lys Val 290 295
300Trp Cys Ala Ser Gly Arg Ser Lys Val Ile Lys Gly Ser Leu Pro
Leu305 310 315 320Ile Gly Glu Ala Asp Cys Leu His Glu Lys Tyr Gly
Gly Leu Asn Lys 325 330 335Ser Lys Pro Tyr Tyr Thr Gly Glu His Ala
Lys Ala Ile Gly Asn Cys 340 345 350Pro Ile Trp Val Lys Thr Pro Leu
Lys Leu Ala Asn Gly Thr Lys Tyr 355 360 365Arg Pro Pro Ala Lys Leu
Leu Lys Glu Arg Gly Phe Phe Gly Ala Ile 370 375 380Ala Gly Phe Leu
Glu Gly Gly Trp Glu Gly Met Ile Ala Gly Trp His385 390 395 400Gly
Tyr Thr Ser His Gly Ala His Gly Val Ala Val Ala Ala Asp Leu 405 410
415Lys Ser Thr Gln Glu Ala Ile Asn Lys Ile Thr Lys Asn Leu Asn Ser
420 425 430Leu Ser Glu Leu Glu Val Lys Asn Leu Gln Arg Leu Ser Gly
Ala Met 435 440 445Asp Glu Leu His Asn Glu Ile Leu Glu Leu Asp Glu
Lys Val Asp Asp 450 455 460Leu Arg Ala Asp Thr Ile Ser Ser Gln Ile
Glu Leu Ala Val Leu Leu465 470 475 480Ser Asn Glu Gly Ile Ile Asn
Ser Glu Asp Glu His Leu Leu Ala Leu 485 490 495Glu Arg Lys Leu Lys
Lys Met Leu Gly Pro Ser Ala Val Asp Ile Gly 500 505 510Asn Gly Cys
Phe Glu Thr Lys His Lys Cys Asn Gln Thr Cys Leu Asp 515 520 525Arg
Ile Ala Ala Gly Thr Phe Asn Ala Gly Glu Phe Ser Leu Pro Thr 530 535
540Phe Asp Ser Leu Asn Ile Thr Ala Ala Ser Leu Asn Asp Asp Gly
Leu545 550 555 560Asp Asn His Thr Ile Leu Leu Tyr Tyr Ser Thr Ala
Ala Ser Ser Leu 565 570 575Ala Val Thr Leu Met Ile Ala Ile Phe Ile
Val Tyr Met Val Ser Arg 580 585 590Asp Asn Val Ser Cys Ser Ile Cys
Leu Tyr Pro Tyr Asp Val Pro Asp 595 600 605Tyr Ala
6101718PRTArtificial SequenceIgE Leader Amino Acid Sequence 17Met
Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val1 5 10
15His Ser189PRTArtificial SequenceHA tag amino acid sequence 18Tyr
Pro Tyr Asp Val Pro Asp Tyr Ala1 5
* * * * *